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Known as direct-to-consumer advertising (DTCA), pharm ceutical companies in the 
United States are permitted to advertise prescription drugs directly to consumers. The 
purpose of this quantitative study was to determine if an association exists between 
DTCA and health care-seeking behaviors. The theoretical framework for this study 
involved social learning theory, information integration theory, and prospect theory. The 
research questions identified if exposure to DTCA (a) is associated with physician office 
visits, (b) influences a patient/physician conversation regarding a prescription, (c) 
influences requesting a prescription, and (d) has an impact on patients’ ratings of the 
overall interaction with the physician. Data were derived from an online survey adapted 
from the U.S. Food and Drug Administration. Participants included 235 college-affiliated 
adults. Data were analyzed using descriptive statistics and analysis of variance. The 
Bonferroni correction was used to control the family-wise Type I error rate. The most 
significant findings of this study are that DTCA is a sociated with patients asking more 
questions, having more office visits, and patients having a lower overall health status. 
Future researchers should consider a non-college-affiliated sample and the post-
implementation impact of the Affordable Care Act. This study helps to address the 
community challenges of how DTCA impacts prescription drug use and costs, as well as 
patients’ understanding of the associated risks. Having knowledge of the impact of 
DTCA can help patients and their communities, employers, and governments make more 
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Chapter 1: Introduction to the Study 
Background 
The number of people taking prescription medications is on the rise. In 1993, the 
average number of prescriptions per person annually w s seven, compared to 11 in 2000, 
and 12.1 in 2011, with West Virginia reaching a high of 19.3 (National Center for Health 
Statistics, 2014). In the United States alone, the total annual retail sales for prescription 
drugs filled in 2011 was $228 billion (National Cent r for Health Statistics, 2014). Over 
half of all people in the United States take a minium of one prescription medication 
daily, on average (National Center for Health Statis ics, 2014). Additionally, 
Pharmaceutical Research and Manufacturers of America (PhRMA; 2011) spent $28 
million in 2009 lobbying members of Congress (Blumenthal, 2010). Despite safety 
concerns for certain prescriptions and the unknown effects of others, people rely on 
medications for numerous reasons. There is also concern about drug quality (Tognoni, 
Toussaint, Herxheimer, & Schaaber, 2014) and the association between research and 
advertising (Koch, Brandenburger, Türpe, & Birringer, 2014; McCarthy, 2014; Sacks et 
al., 2014; Sood, Kappe, & Stremersch, 2014). This worldwide drug dependency, 
questions about physician reliance and ethical decisions (Graf, Miller, & Nagel, 2014), 
and the involvement of medical financial resources (Jofre, 2014; Kmietowicz, 2014) have 
all created concerns about how pharmaceutical firms are portraying or marketing their 





These concerns, at least in part, are centered in whether the quality of direct-to-
consumer advertising (DTCA) creates a positive net benefit when compared to ethical, 
social, and economic costs (Kesselheim, 2013; Lansing & Vohra, 2013; Lichtenberg, 
2011; Rusthoven, 2014). D. Lee and Emmett (2012) found that physicians are concerned 
about denying patients’ requests for advertised prescription medications. There is a need 
for further comprehensive research of direct-to-consumer marketing (DTCM) and DTCA 
to determine whether DTCA stimulates patients to seek prescription drugs that they do 
not need (Jureidini, Mintzes, Raven, & Block, 2008; Kulkarni, 2014; McKinlay, 
Trachtenberg, Marceau, Katz, & Fischer, 2014; Moore, 2014a).  
In this study, I focused on advertising (specifically DTCA) in the overall 
marketing field. Hawthorne (2010) claimed that the practice of advertising directly to 
consumers was an event that preceded the existence of th  U.S. Food and Drug 
Administration (FDA). DTCA can be defined as using the lay media as a tool to promote 
prescription drug information to the public (Ventola, 2011). Marketing directly to the 
consumer is not a new practice. It was common during the 19th century to find phony 
medicines advertised in newspapers. These advertisements often claimed that the 
advertised medicine had healing abilities. Debates exi ted even then over the advertising 
and the legal and ethical aspects of marketing campaigns aimed at the general public. In 
the 1900s, the American Medical Association (AMA) tried to end public advertising by 





Critics during this time period accused the AMA of trying to control the medication 
purchasing process for financial gain. 
There has been a transition from the traditional approach wherein pharmaceutical 
companies targeted physicians to introduce new products and to increase the use of their 
products. In the mid-1990s, focus was redirected on the end users of prescription drugs 
(Hawthorne, 2010). With pressure from the pharmaceuti al industry and other parties, the 
FDA, which has been the U.S. regulatory body for presc iption medication since 1962, 
has changed its position on marketing campaigns aimed directly at consumers 
(Hawthorne, 2010). The first DTCA advertisement occurred in 1983, which is when the 
FDA requested industry assistance in developing a formal policy. A draft of this guidance 
was presented to the FDA in 1997, with the final version issued to the industry in 1999. 
The regulations required the inclusion of a brief summary of product in print 
advertisements. Possible drug side effects, contraindications, and effectiveness were 
required disclosures information for each drug summary.  
The United States and New Zealand are the only two countries that allow DTCA. 
Many countries have strict prescription requirements; in some countries, physicians must 
provide patients with a password to access information on the Internet to a drug 
company. DTCA presents its own set of challenges for advertising practitioners due to 
the possible harmful impact that medicines can have; however, as a whole, ethics in 
advertising is a difficult balance to achieve. Despite these challenges, the practice of 





spend twice as much on advertising as they do on resea ch and development (Tadena, 
2010). They also court physicians (Moore, 2014b). The pharmaceutical industry has one 
of the highest profit margins of any industry, with the top pharmaceutical companies, 
including Pfizer, GlaxoSmithKline, and Bristol-Myers Squibb (Kornfield, Donohue, 
Berndt, & Alexander, 2013). As of 2010, Pfizer media spending reached $967.5 million, 
with Lipitor as the top advertised drug (Bulik, 2011). Advertisement spending increased 
from $700 million in 1996 to $5.4 billion in 2006 (Bulik, 2011). However, the spending 
declined by 20% from 2006 to 2010 (Bulik, 2011). The suggested causes for this decline 
include a decline in the number of new drugs, a declin  in consumer spending, and 
consumer skepticism (Bulik, 2011). 
Supporters of DTCA list several factors to support the practice, which include the 
empowering of consumers with information, public health awareness, and improved 
compliance with medication regimens. Those in support of DTCA argue that, by giving 
individuals better information, more informed health decisions can be made (Hawthorne, 
2010). Providing this information is viewed by some supporters as a right to which each 
person is entitled. Also, with DTCA, people are becoming more in tune with their health 
condition and there is an overall greater awareness of medical conditions (Hawthorne, 
2010). DTCA supporters believe that advertising has resulted in the general public 
becoming more comfortable with discussing medical conditions, as well as discussing 
such concerns with their physician. Supporters alsorgue that the final decision to 





that there may be other possible treatments (Ahn, Park, & Haley, 2014; Liang & Mackey, 
2011). These positions all assume that patients possess adqu te understanding and 
knowledge to interpret technical information. 
There are possible risks associated with taking prescription medications. 
Opponents of DTCA claim that DTCA fails to provide accurate information, increases 
physician time to correct misconceptions, ignores prevention and focuses on cure, and 
increases costs to the health care system (Huh & Shin, 2014). Opponents argue that 
advertisements, especially via TV commercials, cannot adequately cover these issues 
(Hawthorne, 2010). Additionally, many drug advertisements are the same as 
advertisements for basic and harmless other products. Although a physician’s 
prescription is still required, DTCA can be a manipulative technique (Huh & Shin, 2014; 
Moore, 2013). Hawthorne (2010) suggested that the decision to take medications is not a 
simple process; rather, it is one that involves diagnostic tests, family history analysis, 
possible interactions, and other important elements. For these reasons the decision to take 
a prescription involves the consideration of many factors and exposure to DTCA may or 
may not be sufficient alone to make a final decision.    
Studies have been conducted on exposure to DTCA for specific diseases. Jureidini 
et al. (2008), using a prior study conducted by Block (2007), examined the net social 
benefit of DTCA of antidepressants. Block used a DTCA survey and other empirical 
research to analyze care-seeking behavior when expos d t  antidepressant advertising. 





However, Block argued that a net benefit would exist even if all people in the United 
States were treated with an antidepressant. Jureidini t al. claimed that Block’s model, 
which included four steps, was missing a step. In the original study, the four steps 
included the following: the number of people exposed to advertising that motivates 
treatment, those with clinical depression, those who may or may not have depression but 
who receive prescriptions, and those who benefit from drug treatment. The step missing 
from Jureidini et al.’s study involved looking at the proportion of people experiencing 
harm from the prescription for both those having and not having depression.   
The differences in the two DTCA research approaches in studying depression 
includes arguments regarding the use of various estimates. Block (2007), using data from 
the FDA, the Henry J. Kaiser Family Foundation, andfrom the U.S. National Ambulatory 
Care Survey, estimated that 4.59 million (9.4%) of 48.9 million consultations would have 
been stimulated by DTCA in 2000. Additionally, Block estimated that, for the same year, 
5.85 million people experienced untreated depression. H wever, Jureidini et al. (2008) 
argued that Block’s estimates were overly high. One example of Block’s overestimate, 
according to Juriedini et al., was that the number of untreated people in the United States 
was derived from a subset in which there was minimal pairment, which goes against 
meeting the diagnostic criteria. Although Jureidini et al. stated that Block’s work 
contributed to the DTCA debate, there were some notd weaknesses. Jureidini et al. 
concluded that advertising for antidepressants via television is presented in a seductive 





(2013) stated that DTCA is an educational tool thathas benefited the patient by involving 
them in the decision making process. A patient may research their condition and the 
various available drugs once they are exposed to DTCA. Although physician approval is 
needed for a prescription, the patient is no longer relying solely on the physician.   
Extensive research on DTCA is limited. However, the FDA Office of Prescription 
Drug Promotion (OPDP) has researched and continues to r search this topic. Most 
studies conducted by the OPDP have been experimental in ture (HHS, 2004). The 
survey that was used for the present study was taken from the only research conducted by 
the OPDP using this type of research method. As such, the present study added to the 
growing body of research in this field. 
Statement of the Problem 
There are potentially significant adverse public health care consequences posed 
by DTCA, such as overuse, cost burden on patients, xploited public policy, and wasted 
limited resources. DTCA, or prescription drug advertising, is permitted by the FDA, the 
regulating government agency in the United States (HHS, 2004). The FDA attempts to 
assure safe drugs for both human and veterinary use. The office within the FDA that 
investigates the applied/theoretical issues relating to the communication of risk and 
benefit for DTCA and professional promotional presciption drug material is the OPDP.   
The pharmaceutical industry is a profitable business. Additionally, DTCA has 
grown exponentially from less than $1 billion in 1996 (Bulik, 2011) to $4.2 billion in 





(Ghosh & Ghosh, 2010). Pharmaceutical firms record more than $300 billion in sales 
revenue annually (Spurling et al., 2010). Provider targeting promotion has reached $36.1 
billion (Kornfield et al., 2013) and improper drug se costs U.S. employers more than 
$276 billion (Conlon et al., 2012) in lost productivity, accidents, and health care costs. 
Additionally, developing countries are now spending 20-60% of their health budgets on 
prescription drugs, and governments tend to pay above-market rates, straining already 
limited governmental resources (Greene & Kesselheim, 2010). Finally, several 
pharmaceutical firms have paid settlements of $2.3 and $3 billion when confronted with 
allegations of inappropriate off-label marketing (Kesselheim, Mello, & Studdert, 2011; 
Matthews, 2013; Outterson, 2012). The examples of the above settlements and the overall 
possibility for large profits suggest the need for regulations and supervision.   
The 340B Drug Discount Program was created by Congress in 1992 to provide 
significant discounts to organizations providing care for the indigent. Despite good 
intentions, the program has resulted in abuses that victimize the patients that the program 
was designed to help. Through an unrealized contractual loophole, health care 
organizations were able to increase their profit margins, while not passing on the 
expected discounts to indigent patients (Bress, 2014; J. Lee, 2013; Pollak, 2013). From a 
public policy perspective, this loophole provides an incentive to entice patients, 
especially the indigent who tend to be less educated (Kaushal, 2014; Robbins, Stillwell, 





Marketing of prescription drugs is distinctive in tha  potential risks to the patient 
in the marketing of these drugs are required to be disclosed by the FDA. However, 
patient perceptions about these advertisements may be distorted, given their often limited 
clinical understanding. In many cases, patients are eith r not afforded adequate time and 
or lack the ability to fully understand the risks and benefits of prescription drugs (Bishop 
& Salmon, 2013; Herbst, Hannah, & Allan, 2013). Not fully understanding the side 
effects, complications, and the cumulative interactions of prescription drugs presents a 
potential risk of injury or even death for patients. Additionally, although physician 
assistance is required, exposure to these types of advertisements may encourage 
medication-seeking behaviors (Bishop & Salmon, 2013; Bradford & Kleit, 2011; 
Callaghan, Laraway, Snycerski, & McGee, 2013; D. Lee & Emmett, 2012). In this study, 
I used the social learning theory, information integration theory, and prospect theory to 
examine consumer behavior as it relates to DTCA of prescription drugs. 
Purpose of the Study 
The purpose of this quantitative study was to determine the possible association 
between DTCA and health care-seeking behaviors and to explore patient perspectives on 
DTCA relative to patients’ overall health care experience. If there is a link between the 
advertising component of marketing campaigns and healt  care-seeking behavior, an 
overuse of unnecessary medications and a subsequent decline in health status, wasted 





and governments. FDA guidance and regulations, federal and state health care policy, and 
patient interaction with health care professionals are all impacted by DTCA. 
Researchers remain unclear about the impact of DTCA on patient behavior 
(Callaghan et al., 2013; Lee-Wingate & Xie, 2013; Mukherjee, Limbu, & Wanasika, 
2013; Niederdeppe, Byrne, Avery, & Cantor, 2013). This study will help to fill this gap 
and provide a deeper understanding of the possible association between DTCA and 
patient behavior. Additionally, given the concerns a d risks associated with inappropriate 
prescription drug use (Mackey & Liang, 2013), an additional purpose of this study is to 
provide information for more socially responsible decision making for both patient and 
doctor.    
Research Questions and Hypotheses 
The following research questions were addressed in detail and acted as a catalyst 
for this study:  
1. What is the relationship between direct-to-consumer advertising (DTCA) 
and physician office visits? 
2. What is the relationship between direct-to-consumer advertising (DTCA) 
and patients asking for a prescription?  
These questions were researched through two hypotheses. The independent 
variable in this study was patient exposure. The dependent variables were physician 





independent variables were significantly associated with patient health care-seeking 
behaviors. Hypothesis 1 is related to physician office visits and exposure to DTCA: 
H10: There is no relationship between patient exposure to DTCA and subsequent 
physician office visits. 
H1a: There is a direct association between patient exposure to DTCA and 
subsequent physician office visits. 
Hypothesis 2 is related to requests for a specific prescription medication and exposure to 
DTCA:  
H20: There is no relationship between patient exposure to DTCA and a patient 
asking subsequently for a corresponding prescription drug. 
H2a: There is a direct association between patient exposure to DTCA and a 
patient asking subsequently for a corresponding prescription drug. 
Model components are depicted in Table 1. Chapter 3 provides a detailed 
description of the research methods and techniques us d to analyze the hypotheses.  
Table 1. 
 
Components of the Model 
Hypotheses Independent variables Dependent variables 
1 Patient exposure Physician office visits 







In this study, the theoretical framework consisted of social learning theory, 
information integration theory, and prospect theory t  examine consumer behavior as it 
relates to DTCA of prescription drugs. Bandura’s (197 ) social learning theory includes 
elements of conditioning and learning with cognitive aspects, while extending internal 
factors to explain behavior. Social learning theorists attempt to clarify behavior by 
examining environmental influences (Thorpe & Olson, 1990). Reciprocal determinism is 
the term used to explain the interactional process that applies to the shaping of behavior 
(Bandura, 1971). The interactions between the enviro ment, the person, and the behavior 
have an equal impact on or influence of one another. Such interactions can include 
situations in which a person makes self-adjustments or when a person talks to himself or 
herself. Reciprocal determinism is important in explaining how a person learns by 
observing or modeling.   
There are various theories that attempt to explain how learning occurs. Bandura 
(1971) argued that the majority of learning is gained through a person’s direct 
experiences or secondhand observations. Thorpe and Olson (1990) presented three effects 
of learning: observational learning effects, inhibitory and disinhibitory effects, and 
response facilitation effects. When a person uses pr viously learned responses in new 
situations, this behavior demonstrates observational learning. In inhibitory and 
disinhibitory effects, a person can repeat or not repeat an observed behavior of a model 





the behavior, an inhibitory effect occurs. With disinhibitory effect, the observer is 
encouraged by the observed behavior. Response facilitation effects can be described as 
observing a behavior that is defined as acceptable and following four steps in the 
modeling process.  
In the learning process the observer first observes th  model and then retains the 
information. The observer then compiles all of the observed information together and 
then, in the final steps, the actual modeling of the behavior occurs (Thorpe & Olsen, 
1990). Modeling can take on many forms in addition  an actual live model or 
observation. Modeling can also take place from observing media, television, and so on. 
This type of modeling is known as symbolic modeling (Thorpe & Olsen, 1990). Also, 
covert modeling can take place in which the observer imagines observing a model 
(Thorpe & Olsen, 1990). According to Bandura (1969), imitating an observed behavior 
does not have to immediately occur following the observation. A person may not be 
aware of the observed images or the imitation of the observed behavior.   
Studies have been conducted on DTCA and modeling.  One example of this is 
when Welch Cline and Young (2004) conducted a content analysis based on Bandura’s 
(1971) social learning theory. The purpose of the Welch Cline and Young study was to 
identify features of DTCA that may function as modeling. Visual cues were examined as 
vicarious motivators. According to Bandura’s social le rning theory, when a behavior is 
observed, the possible observed rewards can become motivators. Specifically in DTCA 





study consisted of reviewing advertisements in 18 popular magazines for a 2-year period, 
from January 1998 to December 1999. Four research questions were developed:  
1. What percentage of direct-to-consumer print advertis ments depicted 
models?   
2. What are the demographic characteristics of models depicted in direct-to-
consumer print advertisements?   
3. What are the nature and frequency of identity rewards offered in direct-to-
consumer print advertisements via visual cues?  
4. What are the natures and frequency of relational rewa ds offered in direct-
to-consumer print advertisements via visual cues, respectively?   
Welch Cline and Young (2004) indicated that more than 80% of the advertisements 
contained models and 35.7% included inanimate objects. Welch Cline and Young also 
indicated the use of either male or female models in advertisements; 33.3% of the ads 
used more female models than men. Advertisements with only African Americans, 
Hispanic Americans, or Asian Americans were few: 14.2%, 1.1%, and .5%, respectively. 
In 91.8% of the advertisements, people who appeared healthy were depicted. Welch 
Cline and Young concluded that changes in health care behavior might be triggered by 
DTCA. Consumers are often exposed to visual models with positive features, such as 
being active and friendly. 
An example of another study focused on the nonmedical use of prescription 





drug use by individuals between the ages of 18 and 25 in the San Francisco Bay area. 
Social learning theory was used as a framework to understand the learned and imitated 
aspects of deviant behavior. Mui et al. found that rough differential association, 
imitation, definitions, and differential reinforcemnt, social context can set the stage for 
behavior. Nonmedical drug use is popular among young adults and social learning theory 
provides support for the framework for understanding the initiation of nonmedical drug 
use.  Also, from the 120 total participants in the Mui et al study, 73.3% were currently 
attending college.   
In comparison differences between social learning theory and information 
integration theory.  According to social learning theory (Bandura, 1971), behavior is 
examined as related to environmental influences, whereas information integration 
theorists (Anderson, 2014) examine how various sources of information are integrated 
internally by a person. Information integration theory was proposed by Anderson (2014) 
and was developed around four concepts: stimulus integration, stimulus valuation, 
cognitive algebra, and functional measurement. The fundamental concept in integration 
theory is that the way in which a person thinks or behaves depends upon multiple stimuli 
acting in cooperation with one another. Anderson’s (2014) four concepts interlock when 
physical stimuli impose upon a person. Integration function combines the transformed 
psychological stimuli into an implicit response, which is then externalized using the 
response function. A person uses simple algebraic rules on the stimulus information 





Prospect theory is used to examine how a person makes decisions. Developed by 
Kahneman and Tversky (1979), prospect theorists attempt to describe decisions that are 
made in which a person makes a choice among alternatives when risk is involved. There 
are two phases in the decision process: editing and evaluation. During the editing phase, 
there is an initial analysis of the possible alternatives and the outcomes for a decision. 
This stage is followed by an evaluation of the alternatives, with the highest value choice 
selected. During the narrowing of alternatives, distinguishing features are evaluated in 
terms of gains or losses, while similar components are disregarded, demonstrating the 
isolation effect (Nickerson, 2012). 
Nature of the Study 
In this study, I used a quantitative approach to determine the association between 
DTCA and health care-seeking behaviors. Survey data were collected using a virtual 
bulletin board accessible to students who attended an online university and 
SurveyMonkey. Various research studies are regularly available on the virtual bulletin 
board. Students who show an interest can participate in a research study after completing 
an online informed consent form prior to the survey.  
The collected data were analyzed and compared to data av ilable in the public 
domain from documents obtained by the U.S. Department of Health and Human Services 
(HHS; 2004), of which the FDA is an agency. Specific reviews of prescription drug 
advertisements and promotional labeling are regularly performed by the FDA OPDP. The 





questions and the variables were measured based upon the responses. The results of the 
FDA study were published in 2004; however, the data were collected in 1999 and 2002 
from telephone surveys.  
In this study, I used the same 2004 survey instrument used by the HHS, but via 
online survey. The survey instrument is located on a public domain. The data were 
analyzed using analysis of variance (ANOVA), which were employed to test the 
hypotheses of this study. With each analysis, statistical significance and predictive value 
were assessed as applicable. Statistical Package for the Social Sciences (SPSS), Version 
21, was used for all data analyses, and statistical s gnificance was assessed at the p < 0.05 
level. Finally, the predictive power of the two equations was compared to determine the 
predictive value of DTCA. Further analytical details are provided in Chapter 3, with 
results presented in Chapter 4. 
Definitions of Terms 
 The following technical terms are used in this study:  
 Direct-to-consumer advertising (DTCA): A component of direct-to consumer 
marketing that involves the practice of presenting advertising material directly to the 
possible user rather than to the physician (Rollins & Perri, 2014). 
 Direct-to-consumer marketing (DTCM): A method of marketing that links 
consumers and suppliers together through comprehensive, systematic, market-based 
planning, managing, promoting, and advertising of pr ducts directly to consumers  





 Foreign consumer culture positioning (FCCP): A marketing position associated 
with a particular foreign culture (Alden, Steenkamp, & Batra, 1999). 
 Food and Drug Administration Amendments Act (FDAAA; 2007): A law that 
added provisions to the Federal Food, Drug, and Cosmetic Act, which gives the FDA 
authority to regulate drugs and other products. 
 Global consumer culture positioning (GCCP): An alternative approach to brand 
positioning that is designed for international marketing. GCCP involves sharing symbols 
that denote membership in a global consumer segment (Alden et al., 1999). 
 Local consumer culture positioning (LCCP): An approach to marketing that is 
associated with a particular local culture (Alden et al., 1999). 
 Patient exposure: A patient’s recall of seeing or hearing any advertis ment for 
prescription drugs (HHS, 2004). 
 Physician office visit: A face-to-face, care-driven interaction with a physician, 
physician assistant, or nurse practitioner working for a physician (HHS, 2004) 
 Voluntary simplicity: The source of personal satisfaction and happiness coming 
from nonmaterial aspects of life (Shaw & Newholm, 200 ).  
Assumptions 
In conducting this study, I assumed that all participants responded truthfully to the 
survey and that all participants had access to the Internet or a computer. Additionally, I 
assumed that respondents to the HHS surveys, which were used for comparative 





statistical methods employed in this study were reliable and representative of the national 
population. Additionally, I assumed that the influenc  of mass media on society 
(Bandura, 2001) is substantial and the pharmaceutical industry is aggressive in nature 
(Angell, 2011). 
Scope and Limitations 
I collected data via an online survey posted on two survey websites: a university 
participant pool and SurveyMonkey. The survey was adapted from the research 
instrument used in 2004 by the FDA. Only college students participated in the present 
study. However, the original data were collected from three national surveys (two surveys 
involving patients and one survey involving physicians) conducted by telephone. The 
original FDA population consisted of individuals in the United States with a listed or 
unlisted telephone number. No monetary incentive was offered in the FDA study or in the 
present study.   
 One possible limitation to the present study was the sample size. Due to the 
voluntary nature of this study, there was not a large sample. Sampling error can occur 
when some persons in the population are omitted (Fowler, 2014). To address this 
concern, the minimal sample size was calculated. The inclusion criteria for this study 
included adult students who had visited a health care provider within the last year for a 
health condition of their own (the same inclusion criteria used in the original FDA study).   
The comparative data used in this study were collected in the Patient and 





Drugs study conducted by the FDA in 2004. Although the OPDP has conducted other 
research relating to DTCA, the 2004 study conducted by the FDA was the only survey 
type study at the time the present study was conducte . Because the 2004 FDA study was 
one of the first studies in the area, only general questions were used on the instrument. 
Also, no analysis of the comprehension of the advertisement was included. Additionally, 
the FDA survey did not distinguish the type of medium for the DTCA exposure, which 
may differ from television, print, Internet, or radio. Although a random sample of 
telephone numbers (including both listed and unlisted numbers) were included in the 
FDA study, individuals without such service were not represented in the present study. 
Additionally, like the previous FDA study, the research instrument used in the present 
study was administered only in the English language.  
Significance of the Study 
 The purpose of this study was to determine the association between DTCA and 
health care-seeking behaviors in an academic community and to explore patient 
perspectives on the issue related to the patients’ overall health care experience. If there is 
an association between the advertising component of DTCM and health care-seeking 
behavior, then there could be an overuse of unnecessary medication. Additionally, 
patients who receive and consume unnecessary medication may experience a subsequent 
unnecessary decline to their health status and bear an dditional cost burden. The long-





regulations, changes in federal and state health care policy, and possible changes to 
patient interaction and health care management. 
This study will provide a greater understanding andinsight into opportunities to 
mitigate the potential adverse impacts of DTCA. Overus , inordinate cost burdens on 
patients; health care organizations exploiting loopholes in public policy; patients, 
employers, and governments losing limited resources through inappropriate prescription 
drug use; and the diversion of innovation and research efforts to profitable drugs at the 
expense of drugs that could have a clinical impact are all potential negative outcomes 
resulting from inappropriate DTCA (Suh, 2012). Additionally, physicians feeling 
pressured to switch patients from known, effective, less expensive and older medications 
to new, more profitable medications, as well as the pot ntial increased physician 
workload that may prevent more ill patients from obtaining limited appointments are 
other negative outcomes that this study can help to prevent. DTCA has a potential that 
can be leveraged for good, provided that responsibility is exercised. 
As pharmaceutical companies are viewed as one of several contributors to the 
sustainability of the health care industry, this study can provide information on focusing 
DTCA efforts to help improve the availability, dependability, capability, affordability, 
and marketability of prescription drugs. As outlined by Mathaisel and Comm (2014), 
these abilities can help the health care industry to minimize waste, create value, and 
remain productive for the long term. According to Mathaisel and Comm, the United 





Organization. Further, of the seven industrialized nations, “the U.S. ranked last on 
quality, efficiency, access, equity and ability forcitizens to lead long, healthy lives” 
(Mathaisel & Comm, 2014, p. 1046). In terms of cost-benefit, the United States is viewed 
as a poor “value” for health care, given the higher expenditures per capita that fail to 
yield the expected benefits or outcomes. Along with patient overtreatment, medical 
errors, failures in coordinating care, confusing burea cracy, and fraud, pharmaceutical 
firms are believed to contribute to this less-than-optimal performance. This study will 
provide clearer information about pharmaceutical company opportunities that could, 
through patients, help to reverse these adverse national rends. 
Increase in the use of DTCA by pharmaceutical companies suggests that this 
practice is profitable (Sanky, Berger, & Weinberg, 2012; Yaqub, 2014). Given the 
potential opportunity for positive or negative impact, Goldberg (2013) called for more 
quantitative assessments of DTCA to better understand i s impact. This study will help to 
address this gap in the literature and offer opportunities for focusing further research in 
more appropriate areas. By providing a clearer understanding of the impact of DTCA, 
this study will provide managers and executives, as well as governments and legislatures, 
with information that can help to guide policy development, strategies, and health plan 
decisions. This guidance can help to ensure that patients have adequate information to 
make appropriate decisions, may drive education-adjusted DTCA, and can help to reduce 
risks for patients. Also, guidance has the potential to reduce costs for governments and 





information can also help to redirect limited economic resources to provide a greater 
impact on society by supporting a healthier workforce and economy (Huebner, 2014). 
The pharmaceutical industry has the potential and ability to positively or negatively drive 
hundreds of billions of dollars of direct costs and unknown billions in indirect or soft 
costs.  A deeper understanding of DTCA is necessary for better managerial, clinical, and 
health policy decisions. 
Summary 
 DTCA is a lucrative practice in the pharmaceutical ndustry. With the overall 
financial success of this industry using DTCA and the associated demand for significant 
returns by investors, discontinuing such practices s not likely. Regulation by the FDA 
attempts to protect the public; however, patient healt -seeking behaviors are a concern. 
The purpose of this study was to determine the associati n between DTCA and health 
care-seeking behaviors, which were researched throug  two hypotheses. Additionally, 
patient perspectives were explored as they related to the overall health care experience. 
This study was quantitative and used an online univers ty participant pool and 
SurveyMonkey to collect survey data. The survey instrument administered in the present 
study was used in the original FDA (HHS) 2004 study. The independent variables were 
patient exposure to advertising, sociodemographic caracteristics (i.e., age, gender, 
income, and ethnicity), health status, and education. The dependent variable, health care-
seeking behaviors, were composed of two variables: physician office visits and asking for 





Honesty by the respondents to the original FDA study and the present study, the 
influence of mass media, and the aggressive practices of pharmaceutical companies were 
assumptions of this study.  
 The remainder of the study is organized as follows. Chapter 2 includes a review 
of the literature on the subject. Chapter 3 contains  explanation of how the study was 
designed. Chapter 4 includes a discussion about the outcomes of the study. Chapter 5 
includes a discussion about the conclusions drawn from the study and an explanation of 





Chapter 2: Literature Review 
This review of the literature includes a discussion about the history of the FDA, 
which monitors advertising of prescription drugs. Literature that encompasses various 
positions regarding the DTCA debate is also included, as well as literature about the 
impact of DTCA on pharmaceutical companies and healt  policy. The theoretical 
framework section includes social cognitive theory, choice, and agency theory as related 
to advertising. Global consumer culture positioning is addressed in this review. The field 
of research on this topic is limited; however, it continues to grow (Goldberg, 2013). Most 
studies conducted by the FDA have been experimental in nature. Several researchers 
have used data from the original FDA (HHS, 2004) study to further this research base. 
However, patient attitudes may have changed over the last 10 years. The present study 
adds to the current field of research and serves as a comparison to other study findings.     
Title Searches, Journal Articles, and Research Documents 
I used refereed journal articles, scholarly books, and research documents through 
Internet search engines that included ProQuest Central, ProQuest Health & Medical, 
Academic Search Complete, Business Source Complete, Cumulative Index to Nursing & 
Allied Health Literature (CINAHL) Plus, Communication & Mass Media Complete, 
PsycARTICLES, PsycBOOKS, ProQuest Digital Dissertations, EBSCO ebooks, and 
SAGE Premier. Similar research tools from several local university libraries 






The idea that certain expensive medications can only be obtained with a 
prescription from a physician has stirred controversy. Because there are physician 
incentives for the marketing of these medications to consumers (Jofre, 2014; 
Kmietowicz, 2014), a better understanding of these interactions is warranted. These 
potential conflicts of interest between physician and patient may present significant 
concerns (Brill, 2013; Korn & Carlat, 2014; Perry, Cox, & Cox, 2013). To clarify one 
aspect of this situation, I sought to identify the relationships between DTCA and patient 
medication-seeking behaviors. 
Consumer behavior as it relates to DTCA was considered in this study within a 
theoretical framework that included social learning theory, information integration 
theory, prospect theory, and emerging theoretical constructs from published works. This 
framework served as the basis for the hypothesized relationships between DTCA, office 
visits, asking for a prescription, and several other variables. I considered the potential 
impact of DTCA on patients seeking access to prescription medications that can only be 
obtained from a provider licensed to prescribe substances that are regulated by the FDA. 
History of the FDA and DTCA 
 The Pure Food and Drugs Act (1906) marked the beginning of efforts by the 
federal government to ensure the safety and veracity of medications. Standards and 
quality requirements for pharmaceuticals in Western nations were relatively nonexistent 





prepared distributors created an increased degree of confusion for consumers. This 
confusion was further exacerbated by the limited scientific knowledge of the period and 
the tendency of consumers to exercise several different options (Kastner, 2011), making 
inferences beyond the anecdotal difficult. The increasing potency and danger of 
formulations in the 1930s further transformed the environment by introducing the 
concept of so-called “wonder drugs” with increasingly positive outcomes within the 
advertisements. However, there were significant negative side effects from these 
increasingly potent medications provided support for increased governmental oversight 
and regulation (Kastner, 2011). 
Furthering the aim of public safety, the Federal Food, Drug, and Cosmetic Act 
(1938) gave the FDA oversight of medication production and dispensing to ensure a more 
accurate accounting of the risks and benefits of formulations (Kastner, 2011). Since 1951, 
federal law has required that drugs be prescribed by a physician if they pose a high risk of 
harm if used incorrectly or abused. Through the Kefauver-Harris amendments, the FDA 
was given unprecedented and increasing enforcement authority in 1962 to demand drug 
efficacy and safety from manufacturers and distribuors  (Kastner, 2011). Wellington 
(2010) described DTCA in terms of a human right in which the patient has access to the 
information needed to make health-related decisions.  This view of DTCA gives patients 
informed control over their health related decision. 
With the ultimate goal of public safety and informed consent, the FDA has 





guidance, limits, and restrictions. Achieving this goal, based in clinical research and 
outcomes feedback, has become increasingly complex with the evolving nature of 
formulations and increasing opportunities for off-label usages that are discovered through 
advancements (Sashegyi, Felli, & Noel, 2013; Sawyer, 2012). However, the ratio of 
benefits to harm for patients taking newer medications varies with the marketing of the 
drug (Brody & Light, 2011). 
There are four steps that a pharmaceutical company must take to obtain FDA 
approval. The first step is known as the preclinical trail (Hawthorne, 2010). This process 
involves testing the drug on animals to determine initial suitability for human testing. 
During this stage, the drug company submits summaries of the animal test results and 
discusses the manufacturing process. This stage also requires an outline of how the drug 
will be tested on humans. The second step (Phase I clinical trials) involves testing the 
drug on healthy volunteers to determine safety (Hawthorne, 2010). This trial consists of a 
small group of healthy participants. Stages 3 and 4, also called Phase II and Phase III 
clinical trials, consist of participants with the disease (Hawthorne, 2010). The trials 
during Phases II and III involve a larger participant pool than in Phase I. After 
successfully completing Phase III, a company can submit an application to start selling 
the drug (Hawthorne, 2010).   
The FDA has established standardized guidelines on how long the human trials 
should last to assist companies through this challenge. There are also a general number of 





participants (Hawthorne, 2010). If Phase I is determined to be safe, Phase II would then 
include several hundred people with the disease that the drug is meant to target 
(Hawthorne, 2010). Phase II can last for 2 years before Phase III begins. Phase III 
consists of several thousand patients, typically over the course of 3 years (Hawthorne, 
2010). Another challenge faced by drug companies is FDA bureaucracy involving 
selecting the right- or best-fit division for the pro osed drug within the FDA.   
Like other governmental agencies, the FDA continues to face many challenges. 
Political influence is one of many pressures on the FDA. Hawthorne (2010) presented the 
Reye’s syndrome occurrence in the 1980s to illustrate the extent of this pressure. Reye’s 
syndrome in children occurs after a viral infection and leads to death in 20% of cases; it 
is also associated with mental retardation. The Centers for Disease Control and 
Prevention (CDC) concluded there was a link between R ye’s syndrome and aspirin. 
Although this information was submitted to the FDA, protests from the aspirin industry 
resulted in the FDA withdrawing its decision to require warning labels. The warning label 
requirement was passed by Congress more than 5 years afte  the CDC acknowledgments, 
after an interest group sued the FDA. Another problem of the FDA is a history of having 
approved products that are later found to be dangerous, such as the Bjork-Shiley artificial 
heart valve, which resulted in approximately 500 deaths (Hawthorne, 2010).  
 Drug companies are not required to obtain FDA approval prior to disseminating 
an ad. According to FDA regulations, prescription drug ads cannot be misleading or omit 





regarding the presentation of risks and benefits. Additionally, if an ad is in print, the 
format must include information in a “brief summary bout side effects, 
contraindications, and effectiveness” (Avery, Eisenb rg, & Simon, 2012, p. 252). These 
guidelines attempt to present the necessary information for patients to make informed 
decisions.   
Pharmaceutical Industry and DTCA 
 There can be various reasons why DTCA is used in the industry. Pharmaceutical 
companies often use DTCA in an attempt to improve their brand name, as well as to 
influence patients to use their particular product. Menon, Deshpande, Perri, and Zinkham 
(2003) conducted a study to determine if consumers attend to the brief summary of the 
risk information in the print DTCA. This summary is one of the requirements set by the 
FDA. The secondary objective was to determine if consumers found this information to 
be useful. Data collected from a 1999 national survey on consumer attitudes toward 
DTCA were analyzed. A national sample of telephone numbers was purchased by the 
magazine, with a sample size of 1,205. Ten combined hypotheses for the two objectives 
were developed. For Objective 1, the hypotheses were as follows: 
H1: General consumer characteristics (age, sec, race, and educational level) 
influence whether consumers pay attention to the brief summary. 
H2: Consumers’ interaction with DTCA influence whethr consumers pay 





H3: Consumers’ attitudes toward the concept of DTCA influences whether 
consumers pay attention to the brief summary.  
H4:  Consumer characteristics specific to health care influence whether 
consumers pay attention to the brief summary. (Menon et al., 2003, p. 183) 
For Objective 2, the following hypotheses were develop d: 
H5: General consumer characteristics influence usefuln ss of the brief summary 
in discussions with physicians. 
H6: Consumers’ interactions with DTCA influence usef lness of summary 
discussions with physicians. 
H7: Consumers’ attitudes toward the concept of DTCA influence usefulness of 
brief summary in discussions with physicians. 
H8: Consumers’ attention-related characteristics influe ce usefulness of brief 
summary in discussions with physicians. 
H9: Consumers’ perceptions of the clarity of the bri f summary influence its 
usefulness in discussions with physicians. 
H10:  Consumer characteristics specific to health care influence usefulness of 
brief summary in discussions with physicians. (Menon et al., 2003, p. 183) 
Menon et al. (2003) used a variety of measurement mthods to analyze the data, 
including using yes/no as the dependent variable and demographic factors as the 





 From the consumers surveyed with no missing responses, 438 subjects remained 
with an average age of 42. Additionally, the majority of the participants were women 
(62.5%) and Caucasian (87.58%). In summary, the results from the analyses supported 
H1, H2, and H3. Under Objective 2, H8 and H9 were also supported. However, the 
participants that consumed more prescriptions were significantly less likely to attend to 
the summary, which did not support H4. Additionally, under Objective 2, H5, H6, H7, 
and H10 were all not supported. Menon et al. (2003) reached the conclusion that, when 
attending to the summary of DTCA, the consumer’s age was not relevant and neither was 
the number of prescriptions taken. Also, those who read the entire summary were less 
likely to find it to be useful (Menon et al., 2003).  
 For the last 13 years, Prevention has conducted an annual DTC survey. In 2010, 
the data were prepared by Princeton Survey Research Associates International and 
consisted of a national sample of 1,501 adults. Interviews were conducted via telephone 
and the margin of sampling error was reported at +/- 3%. The results indicated that 
consumers believe that pharmaceutical advertising i presented fairly and balanced in 
magazines and television. This finding is related to the FDA regulated “fair and 
balanced” mandate of presenting the risk and benefits qually. The study also reported 
that, for 5 consecutive years, 79% of consumers have either seen or heard the risk on TV 
ads, 73% had seen or heard the benefits on TV ads, an  48% had seen or heard the 





conversations with their doctor after seeing an ad, which has remained stable over the 
past 13 years (Prevention, 2010)(“Prevention Magazine Releases,” 2010). 
Because the knowledge and understanding required to make safe and appropriate 
medication decisions is so advanced, the general public must rely on the expertise of 
physicians to determine the appropriateness and authority to obtain and consume some 
high-risk medications (Moore, 2014a). This agency relationship moderates the 
conditioning, learning, integration of information, and prospect decisions of the average 
person (Noor, Yap, Kok-Hong, & Rajah, 2014). Within this theoretical model, it is 
suggested that patients, regardless of their sociodem graphic profile, will seek to engage 
their “agent” in their desire to be considered for or obtain prescription medications. 
Newton and Ford (2013) posed the question of whether business and medicine are 
ethically incompatible. They described two types of ethics: professional and market. 
When the professional acts in the interest of the client, the behavior is known as 
professional or fiduciary ethics. In contrast, market ethics involve each side working in 
his or her own interest. In the physician-patient relationship, Newton and Ford (2013) 
described the professional ethic as being reflected in the Hippocratic Oath, which states 
that no harm or wrongdoing will come to the patient (p. 78).  
The economic interests of physicians over patients remains a concern today 
(Rusthoven, 2014). However, many changes have occurred in medicine that affect this 
relationship. Medical facilities have expanded, andthis expansion has increased 





that medicine is a social good has changed to one that considers medicine to be a 
commodity, where patients select services that they can afford. These changes in 
medicine are a few of the many factors that have caused providers to compete for patients 
and make decisions that may be based on profits (Ruthoven, 2014). 
Factors Having an Impact on Health Policy  
The health policy aspirations of the federal governme t, the capitalistic goals of 
big business, and the incentives for pharmaceutical firms and investors, have suggested 
an additional area for consideration (Mackert et al., 2013). Although there is evidence 
that DTCA reduces costs by reducing preventable car used by patient noncompliance 
(Bergner, Falk, Heinrich, & Hölzing, 2013), significant potential downsides exist 
(Rodwin, 2013). The heightened degree of regulation by the federal government may 
have fostered public confidence and reduced perceptions of risk. This reduced perception 
of risk may have also created a secondary effect of encouraging questionable utilization. 
Essentially, because the medications are deemed saf, more consumers who otherwise 
would not seek or even need prescription drugs may desire them. Three of the apparent 
downsides of such questionable utilization are opioid abuse (Fischer, Keates, Buhringer, 
Reimer, & Rehm, 2014), testosterone over-prescribing (Gan, Pattman, Pearce, & 
Quinton, 2013), and the resistance to antibiotics that some organisms have developed due 
to antibiotic overprescribing. This increase in questionable utilization may also lead to an 





An additional concern is one of underuse. On the heels of the Great Depression, 
fear of a recurrence may have influenced health policy towards ensuring that consumers 
did not go without needed medications. An economic theory supporting this argument 
was that underuse would lead to higher prices that exclude the less affluent. The 
combination of these concerns, intents, agendas, and goals are believed to have framed 
the development of advertising, price and patent rules, and guidelines of the period. 
Prices, profits, patents, and advertising were increasingly viewed as vital elements of the 
effective development and use of modern technology. This statement is not meant to 
suggest malicious intent, but is important in understanding the basis and rationale for 
legislative activity and decisions by pharmaceutical firms and associated businesses. 
However, history does suggest that regulatory legislation benefits have been heavily 
weighted towards business and industry, and less so towards consumers (Blair, 2014; 
Jofre, 2014; Kmietowicz, 2014). 
Some of the world’s largest pharmaceutical companies ar  located in the United 
States and Great Britain. Among the largest in the United States are Pfizer, Merck, 
Johnson & Johnson, Bristol-Myers Squibb, and Wyeth. The British companies include 
GlaxoSmithKline and AstraZeneca. As prescription drug prices rise, so does the profit 
margin for these pharmaceutical companies. Americans spend billions of dollars on 
prescription drugs each year. Many pharmaceutical companies argue that high drug costs 
are due, in part, to research and development (R&D). However, Angell (2011) argued 





her position. First, the total amount spent on R&D makes up a relatively small part of the 
drug company budgets (Jack, 2014). Second, the number of completely new drugs 
developed is small. Many drugs are only variations to other already existing drugs 
(Angell, 2011; Boumil & Curfman, 2013). An example of this practice involves Claritin 
(used for allergies) by Schering-Plough, which originally made up approximately one-
third of Schering-Plough revenues before expiration of the patent. In an attempt to regain 
revenues, the company tried to get users to switch to another patented drug, Clarinex, 
which was almost identical to Claritin. The third argument against R&D costs is that 
companies can charge whatever they want for the drugs with no or little restrictions from 
the government (Peterson, 2014). In fact, the same drugs are often priced higher in the 
United States than in other countries. Pricing is driven, in part, by return on investment 
demands by shareholders. 
 Many pharmaceutical companies claim that R&D takes many years and is 
extremely costly. The R&D process is divided into two stages: preclinical and clinical. 
During the preclinical stage, companies try to find promising drugs to treat a targeted 
property. This stage is often computerized and involves testing various molecules to 
possible drug candidates. It is the clinical testing phase that is often expensive (Sashegyi 






Social Cognitive Theory 
Bandura’s (2001) social cognitive theory combines el m nts of conditioning and 
learning with cognitive aspects while extending inter al factors to explain behavior. 
Thorpe and Olson (1990) explained that Bandura’s theory attempts to clarify behavior by 
examining environmental influences. Reciprocal determinism is the term used to explain 
the interactional process in the shaping of behavior. The interaction between the 
environment, the person, and the behavior have an equal impact on or influence of one 
another. Such interactions can include situations in which a person makes self-
adjustments or when a person talks to himself or herself. 
Reciprocal determinism is important in explaining how a person learns by 
observing or modeling. Bandura (1971) argued that te majority of learning is gained 
through a persons’ direct experiences or secondhand observations. Thorpe and Olson 
(1990) presented three effects of learning: 
1. Observational learning effects: Learning that results from combining 
previously learned response in new ways; 
2. Inhibitory and disinhibitory effects: The consequenc s of the model’s 
behavior has an impact on the observer’s behavior. An inhibitory effect 
discourages the observer from engaging in the model’s b havior. Conversely, 






3. Response facilitation effects: Generally, a person performs acceptable 
behaviors after observing others. The consequences observed influence the 
observer’s decision to perform the observed behavior. This modeling process 
begins with a person showing attention to the model, which is then followed 
by some form of retention of the information. Next, the observer attempts to 
put the observed performance together, which sometimes requires small steps. 
The forth step involves modeling the behavior, if the motivational factors are 
acceptable. (Thorpe & Olsen, 1990, p. 72) 
When a person uses previously learned responses in new situations, he or she is 
demonstrating observational learning. In inhibitory and disinhibitory effects, a person can 
repeat or not repeat an observed behavior of a model bas d upon the consequences 
observed. If the observer is discouraged to engage in the behavior, the person is 
exhibiting an inhibitory effect. But, in demonstrating the disinhibitory effect, the observer 
is encouraged by the observed behavior. Response facilitation effects can be described as 
observing a behavior that is defined as acceptable and following four steps in the 
modeling process. First, the observer observes the model and then retains the 
information. The observer then compiles all of the observed information together and 
then, in the final step, the actual modeling of the behavior occurs (Thorpe & Olsen, 
1990).  
Modeling can take on many forms, in addition to an actual live model or 





This type of model is known as symbolic modeling. Also, covert modeling can take 
place, in which the observer imagines observing a model. According to Bandura (1969) 
imitating an observed behavior does not have to immediately occur following the 
observation. 
Bandura’s (1965) experiment on imitation of aggressive behaviors was an attempt 
to explain learning by observation. Bandura used four-year-olds in this experiment on 
imitation of aggressive behavior. The experiment involved each participant individually 
observing an adult perform four aggressive behaviors against a Bobo doll on film. The 
behaviors included both physical and verbal aggression. The adult sat on the doll and 
punched it, hit the doll with a mallet, kicked the doll, or threw rubber balls at the doll (all 
physical behaviors were coupled with verbal aggressiv  statements). The child 
participants then observed the adult being reinforced with snacks and verbally praised; 
punished and scolded; or having no consequence implemented. The children were then 
taken into a room with a Bobo doll and other toys. The findings showed aggressive 
behavior by the children, often with similar actions that resembled those of the model.  
Social Cognitive Theory and Choice Theory 
The role of reinforcement and other elements of social cognitive theory in the 
learning process were compared and debated by  Malone (2002) in a compatibility 
analysis with Glasser’s (2010) choice theory. Although both theories support individual 
responsibility, the two theories differ in regard to views on reinforcement, punishment, 





need that a person possesses is love and belongingness (Glasser, 2010). Behavior is 
described as humanistic, and a person’s behavior is determined by survival, love and 
belonging, power, freedom, and fun (Malone, 2002). The term reinforcement, which is 
used in social cognitive theory, was not used by Glasser due to the external nature that is 
implied by the term. Glasser’s choice theory stresses internal control and views 
punishment as an unethical and ineffective practice. Additionally, punishments and the 
administration of rewards are seen as manipulating nd coercive techniques. Internal 
motivators can be eliminated if behavior is manipulated. Bandura’s (1965) research with 
Bobo dolls illustrated the use of learning by watching others and vicarious punishment. 
One of several similarities between social learning theory and choice theory is the 
decision to perform a learned behavior. A person can le rn a behavior in both theories but 
many decide when or if to perform. Malone (2002) stated that, according to choice 
theory, a person creates images in his or her mind. These images form a persons’ 
personal quality world. A person can retain these images or go to the next step of actually 
acting out the activity. A persons’ actions can be changed in both social cognitive theory 
and choice theory. However, in cognitive theory, changing behaviors is accomplished 
though a person changing the pictures within his or her quality world and not the actual 
alteration of a behavior, as is the case according to social cognitive theory. Human 
behavior is regulated by self-efficacy, and the concept is an important aspect of both 






Social System  
Bandura (2002) discussed how social cognitive theory adapts to human 
development, adaptation, and change as part of the social cognitive theory in cultural 
context. Culture is described as a social system that is diverse and changing; therefore, 
human functioning within culture is unique. According to Bandura, there are three modes 
of agency (an intentional influence on a persons’ functioning, which includes a persons’ 
life circumstances): direct personal agency, proxy agency, and collective agency. 
Whereas personal agency involves a persons’ own direct control over conditions, proxy 
agency relies on others to have a secure wellbeing. Collective agency relates to group 
actions in accomplishing desired outcomes. Bandura stated that people have limited 
direct influence or control over social conditions or institutional practices, and people 
must combine their skills and resources to accomplish many individual goals.  
Cultural differences have an impact on how these thr e modes of agency mix for 
successful functioning. All three types of agency are needed each day, regardless of the 
specific culture. Despite the agentic blend, personal efficacy plays a critical role in a 
persons’ actions. Personal efficacy is a persons’ beliefs regarding his or her power to 
produce the desired outcome. Human functioning, which includes cognitive, 
motivational, affective, and decisional processes, are all regulated through a persons’ 
personal efficacy beliefs (Bandura, 2002). 
The role of culture was debated by Bandura (2002) in terms of whether a 





various cultural situations. Both direct and vicarious experiences shape human nature. 
However, biological limits exist that influence the shaping of human nature. These 
biological limits were described by Bandura as permitting a broad range of possibilities 
within a persons’ culture. People adapt to their enviro ments by using various agentic 
modes, while adjusting as needed to overcome physical limitations or restrictions. 
Cultural differences exist both cross-culturally and i traculturally; however, 
“globalization and pluralization of societies” has ended the insular nature of cultures 
(Bandura, 2002, p. 283) Culture is displayed in a persons’ style of living. Culture has an 
impact on a person’s choices. Material and nonmaterial are the two parts of culture. 
Culture can be described as habits that encompass diver e factors to include morals and 
laws (Kahle & Chiagouris, 2014). Additionally, Kolesnik (2013) using Hofestede, 
Hofstede, and Minkov’s (2010) cultural dimensions theory asserted that people from 
different places are distinguished by culture.  
Advertising and Social Cognitive Theory  
The influence of mass media on society is substantial, requiring an explanation of 
the psychosocial role of communication and human behavior. Bandura (2001) described 
psychosocial functioning using a triadic reciprocal usation model that consists of 
personal, behavioral, and environmental determinants. I  general, people are proactive 
and self-reflecting beings. Human nature is shaped or molded by direct and observational 
experiences within biological limits. Behavior is impacted cognitively by external 





situations will be observed. A persons’ own knowledg  and understanding is derived 
from operating symbolically on personal and vicarious experiences (Bandura, 2001).  
 Bandura (2001) also described people as self-reactors. Through internal standards 
and reactions to a persons’ own behavior, one can self-regulate motivation, affect, and 
action. This self-regulation is not limited to negative feedback of oneself, but also on 
motivation. This motivation was described by Bandura as a person setting challenging 
goals and mobilizing resources to accomplish these goals. People have internal standards 
that assess the adequacy of established achievements. Internal standards also regulate 
conduct, both socially and morally. Internal standards can slowly change, but are usually 
stable. Morality (right or wrong) was described by Bandura as inhibitive and proactive. 
Inhibitive morality is a persons’ power to refrain from inhuman behavior, and proactive 
morality is the power to behave humanely. 
Bandura’s (2001) social cognitive theory also described people as being self-
reflective. This process involves a person generating ideas, acting upon them, and then 
judging adequacy. Fours modes (enactive, vicarious, social, and logical) exist in the 
verification of a person’s ideas or thoughts. The fit between a persons’ thoughts and 
action results in what occurs with enactive verification. This type of verification 
corroborates thoughts (a good match) or refutes them (a mismatch). When a person 
observes another’s actions, he or she can check the corr ctness of his or her own thinking 
process, which is vicarious verification. Social verification is conducted when one checks 





fallacies by deducing from known knowledge. Each of these four verification forms can 
produce faulty thinking. Bandura (2001) presented examples of this faulty thinking in an 
illustration in which distorted media versions of reality fostering shared misconceptions. 
In 21st-century society, consumers are presented with images through media that 
would not otherwise be available in their lives. Bandura (2001) summarized four 
subfunctions that govern observational learning, such as through media. The subfunctions 
are attentional processes, cognitive representational processes, behavioral production 
processes, and motivational processes. Attentional processes are those in which a person 
selectively observes modeling. Factors that determine selection include cognitive skills, 
preconceptions, and held values. Bandura described cognitive representational processes 
in terms of memory retention. Observed events must be remembered to be influential; 
therefore, a process must occur that will change or transform the modeled event into a 
useable form. The third process, behavioral production, is the transformation of a concept 
into action. The final process involves motivational aspects that determine what 
encourages a person to perform the acquired behavior, because not all observed behavior 
is performed.  
Conflicts sometimes occur when there is a conflict between observed events and 
internal moral standards. Additionally, vicarious motivators, such as punishment or 
reward, can influence the performance of the observed behavior by an observer. 
According to Bandura (2001), television and other forms of media often glamorize 





motivational element to influence a person’s behavior. Bandura argued that the media can 
both create and alter personal attributes. Technological advances have contributed to 
communicating to large numbers of people in a single transmission.   
DTCA persuades people to use medications that they may not need, creating more 
harm than benefits (Rollins & Perri, 2014). There is also evidence to suggest that DTCA 
has the potential to influence patients’ perceptions f treatment plans (Byrne, 
Niederdeppe, Avery, & Cantor, 2013). Physicians are also not immune to the social 
psychologically based efforts of pharmaceutical firms (Ball & Mackert, 2013; Sah & 
Fugh-Berman, 2013; Sismondo, 2013). New drugs are profitable and, although some 
testing has been done, long-term effects are not known. DTCA influences patients to take 
these new drugs with sometimes unknown risks. The adv rtised drug is often new and 
inferior to older methods, but is more expensive. Established medications are often not 
advertised as heavily because of generic competition (R ss & Kesselheim, 2013; Tenn & 
Wendling, 2014).   
 Pocock (2003) posited for and against non-inferiority t ials, the aim of which is 
the development of new treatments that are safe. A non-inferiority trial refers to a 
“randomized clinical trial in which a new test treatment is compared with a standard 
active treatment rather than a placebo or untreated control group” (p. 483). During 
clinical trials, no patient is supposed to be denied effective treatment. In some trials, there 
may be an active control group and a placebo. Care during clinical trials is important to 





to be avoided. As Pocock (2003) explained, “a Type I error would be the acceptance of a 
useless treatment into widespread use,” and “a Type II error is the failure to use an 
effective active control treatment by adopting a plcebo control group instead” (p. 484). 
Most trials involve the patients receiving the active drug. In some trials, the research 
participant may already know that the new treatment is different from the active 
treatment. 
Even with technological advances, diffusion of information differs among 
individuals and social groups. Bandura (2001) discus ed three processes (innovative 
behaviors, adaptation of behaviors in practice, and social networks) that govern social 
diffusion of new behavior patterns. According to Bandura, the acceptance of new ideas or 
practices is a challenge due to factors such as customs and social unfamiliarity. 
Acceptance then takes on an accelerated course followed by a slowdown in the rate of 
diffusion. The dispersion of innovative behaviors, which is one of the three processes, 
relies on the method of diffusion (e.g., newspaper or television). More complicated 
innovations are more difficult for others to accept. In general, for modeling of a behavior 
to occur, many factors are involved, including human competency and self-belief 
(Bandura, 2001).  
Another process presented by Bandura (2001) is adoption, which relates to the 
many factors that determine if a person will act or engage in a learned behavior. A person 
is more likely to adopt an innovation if there are benefits. These benefits may include 





value system. The third process that has an impact on diffusion is the social network. 
Whether it is an occupational colleague group, friendships, or kinships, people are often 
associated with networks. These networks contain various structural levels and 
interconnectedness; however, no one social network can serve all purposes. A person 
with many network ties is more likely to accept innovations and have a greater likelihood 
of exposure to modeling. Television and online transactions include a few media sources 
that cross barriers (e.g., geographic and time) in the transmission of innovations. The role 
of mass communication plays an important role in learning. 
Social Cognitive Theory and Direct-to-Consumer Advertising  
 Rosenbaum (1999) used Sen’s (1977) work as an origin and comparison for 
research. Sen’s contribution related to culture and consumption. Rosenbaum divided his 
work into six sections. The first section of Rosenbaum’s essay explored various views on 
consumption. Although Rosenbaum defined and summarized consumer theory, beginning 
as early as 1966, a general introduction to Sen’s background and contributions were 
limited for a beginner reader. The second section of the article explored the importance 
and impact of goods on culture. Rosenbaum (1999) rema ked, “In fact, goods receive 
meaning as a consequence of being used as markers and they are used as markers because 
they carry meaning” (p. 322).   
Rosenbaum (1999) suggested that a persons’ identity is established by 
commodities. The roles of preferences, cultural capital, and inequality are followed in the 





unlike Sen’s (1977) suggestion. Rosenbaum’s essay concluded by examining empirical 
evidence related to cultural capital. Here, the author focused on social mobility. Erikson 
and Goldthorpe (1992) debated the determinants of social mobility. Rosenbaum focused 
on how three claims perform in empirical tests, concluding that the evidence presented by 
Erikson and Goldthorpe left some doubt due to the difficulty in representing cultural 
capital empirically in research. Rosenbaum concluded that cultural capital has changed 
over time. He gave the example of the 20th-century pension system that focuses on the 
nuclear family rather than the traditional extended family. In conclusion, considering 
culture is an important element. Individuals choose goods based on symbolic meanings 
derived from their culture (Rosenbaum, 1999). 
The extent of the influence of popular culture may v ry. Cusic (2001) attempted 
to measure the economic impact of popular culture by gathering data from the U.S. 
Department of Commerce. The method by which popular culture is transmitted is the 
media; therefore, advertising expenditures were reviewed. Cusic began with a 
comparison of advertisement figures for 50 years, starting in 1948, which was the first 
full year of television programming. The figures were obtained from the Television 
Bureau of Advertising. In 1948, the most popular advertising medium was newspapers, 
which received $1.745 billion in advertising revenu, compared to $562 million spent on 
radio advertising. In 1948, the total amount spent on advertising was $2.784 billion, of 
which television received 0%, radio 20%, magazines 17%, and newspapers 62.7%. In 





was spent on television advertising, 39% on newspapers, 12% on radio, and 9% on 
magazines. Therefore, over the 50-year period ending in 1994, advertising expenditures 
continued to increase, with the most popular medium changing from newspapers to 
television (Cusic, 2001, p. 1). With the popularity of the internet a shift in the popular 
medium may have changed again. 
Cusic (2001) discussed several possible reasons for the changes in advertising 
channels. One theory suggests that newspaper and television advertising are at-home 
activities, whereas radio penetration is primarily outside of the home. These so-called in-
home activities have a greater chance of being used. The penetration of radio advertising 
may therefore be limited by the reduced amount of time in which listeners engage in this 
type of activity. A second assumption to explain medium changes explored the number of 
radio stations compared to the number of daily newspapers in a market. In a given 
market, there is often one newspaper, but several radio stations. It is more economical to 
advertise in one medium than on several radio stations. Cusic reported that the number of 
U.S. households with cable television increased to 62.4% in 1995, up from 6.7% in 1970. 
The application of these economic findings has an impact on the production of movies, 
music, products, and prescription medications (Cusic, 2001). The practices of marketing 
prescription drugs directly to consumers began in the 1980s, when the FDA removed 
restrictions. The possible effects of such practices on the patient/physician relationship, 
prescription writing, and consumer education are all factors that may experience the 





There have been other studies that have used social c gnitive related theories and 
DTCA.  Welch Cline and Young (2004) conducted a content analysis based on Bandura’s 
(2001) social cognitive theory. The purpose of the study was to identify features of 
DTCA that may function as modeling. Visual cues were xamined as vicarious 
motivators. Social cognitive theory describes behavior change in terms of rewards 
associate with observed behaviors that, in turn, becomes motivators. Motivators may be 
direct or vicarious. In DTCA, financial incentives or claims regarding the potential of a 
product to cure an illness may be direct motivators, whereas images of healthy, happy, or 
socially engaged product users may be vicarious motivat rs (Welch Cline & Young, 
2004, p. 136). The present study used Bandura’s social cognitive theory as part of the 
theoretical framework.   
Many industries, including alcohol and tobacco, engage in social modeling 
through the use of billboard advertisements. Social rewards associated with product 
consumption in advertisements are known as relationl motivators, whereas the use of 
attractive cues are identity motivators. For observational learning to be effective, the 
reader must be attentive to the advertisement and associate a positive image. 
Additionally, the ad must exhibit the same realities of the reader. 
Magazine advertising continues to be a popular medium used by pharmaceutical 
companies for DTCA.  The study conducted by Welch Cline and Young (2004) consisted 
of reviewing advertisements in 18 popular magazines for a two-year period (January 





whether models were present and the number of people in the ad. Illustrations featuring 
rewards were also identified and coded, such as if they were healthy, active, and friendly 
models. The first of the four research questions wa, What percentage of direct-to-
consumer print advertisements depicted models? The results indicate that over 80% of the 
advertisements contained models and 35.7% included inanimate objects. Welch Cline and 
Young further analyzed the advertisements with models by medical condition. 
Advertisements for musculoskeletal conditions and respiratory conditions used people in 
the advertisements 100% of the time. Advertisements for allergies, urologic condition, 
and dermatologic condition depicted people, 94.3%, 92.3%, and 91.7%, respectively. 
Infectious conditions (other than the human immunodeficiency virus [HIV]) and tobacco-
addiction advertisements were the least likely to depict people, both 62.5%, from the 
sampled advertisements. 
The second research question Welch Cline and Young (2004) asked was, What 
are the demographic characteristics of models depicted n direct-to-consumer print 
advertisements? The findings showed that either male or female models were commonly 
found in advertisements 33.3% of the time. The use of f male-only models (38.3%) in 
advertisements was more popular than advertisements co aining only male models 
(26.8%). The authors also found trends in the advertisements based upon the type of 
medical condition. Advertisements for cancer dispropo tionately showed females (75%). 
Other types of medical conditions that depicted women ore often than men included 





(60%). The use of men only by medical condition was popular for such conditions as 
cardiovascular (66.7%) and gastrointestinal-nutritional advertisements (66.7%). 
Advertisements for the drug Viagra (which, for advertising purposes, the type of medical 
condition is presented as undisclosed), depicted both a male and a female model in 100% 
of the reviewed advertisements.  
With regards to ethnic groups, Welch Cline and Young (2004) found nearly three 
fourths of the advertisements (71.6%) depicted Whites only. Advertisements with only 
African Americans, Hispanics, or Asians were few (14.2%, 1.1%, and .5%, respectively). 
Additionally, differences were also found for the type of medical condition and ethnicity. 
The depiction of Whites was dominant in advertisements for cancer, cardiovascular, 
psychiatric-neurological, respiratory, and tobacco-addiction conditions. African 
Americans were most commonly reflected in advertisements for HIV/AIDS and diabetes, 
48.4% and 33.3%, respectively. Hispanics were also more likely to be depicted in 
advertisements for HIV/AIDS, even though this group was less likely to appear in any 
type of advertisement. 
Restating RQ3 and RQ4 of the Welch Cline and Young (2004) study (What are 
the nature and frequency of identity rewards offered in direct-to-consumer print 
advertisements via visual cues, and what is the nature and frequency of relational rewards 
offered in direct-to-consumer print advertisements via visual cues, respectively). The 
findings of Welch Cline and Young’s (2004) study indicated that in 91.8% of the 





the advertisements showed people in some form of activity, social activity (17%), and 
physical activity (43.4%). Most advertisements also sh wed either smiling (72%) or 
friendly (64.1%) behaviors. The depiction of social contexts was found in many of the 
advertisements (40.7%). This social context was often family- or romantically orientated, 
31.1% and 29.8%, respectively.  
Based on these findings, Welch Cline and Young (2004) concluded that change in 
health care behavior might be triggered by DTCA. Consumers are often exposed to visual 
models with positive features, such as active and friendly models. Additionally, over 90% 
of the advertisements showed only healthy-looking people. Exposure to DTCA may be 
misleading and promote stereotypes. Age (Abernathy, Adams-Price, & Henley, 2013), 
ethnicity (Ceccoli & Klotz, 2013), where consumers live (Spake, Joseph, & Megehee, 
2014), and the mode of DTCA delivery (Bhutada, Deshpande, Menon, & Perri, 2013; 
Huh & Shin, 2014; Koch et al., 2014; Vats, 2013) have lso been found to have potential 
impacts on consumers’ perceptions. The present study may add to the debate regarding 
ethical questions surrounding the use of DTCA. This study presents a comprehensive 
discussion regarding the power of DTCA and states that analysis supports observational 
learning, which can influence to relationship between physician and patient. 
Given these theoretical perspectives, patients are beli ved to synthesize 
information that encourages them to seek medications that reduce the disparity between 
their current perceived health status and wellness, and their desired health status and 





belief that the advertised medication could provide better options and more favorable 
health status alternatives. This consumer information processing typology suggests that 
DTCA can make an impact on consumer behavior by developing the cognitive processes 
that synthesize information, develop a need for a change in health status or standing, 
identify a solution to that need, and encourage a dsire to act on that need by seeking 
medications (Mukherjee et al., 2013). 
Moderating and Other Theoretical Constructs  
Most consumers do not possess the educational background, pharmaceutical 
knowledge, or experience to appropriately understand medication risks. Additionally, 
they do not have the authority or ability to obtain prescription drugs without physician 
approval. As a result, social learning, information integration, and prospect theoretical 
postulates must be mediated or at least moderated wi hin the context of agency theory 
(Epstein & Ketcham, 2014). 
Agency theory suggests that situations involving information asymmetry or lack 
of decision-making authority require a qualified “agent” to act on behalf of the consumer 
(Epstein & Ketcham, 2014; Wang, Dou, Li, & Zhou, 2013). Principle-agent relationships 
are found in many industries and products, from real estate to accounting to prescription 
drugs. Associations involving these principle-agent r lationships must involve sound 
ethical and moral standards, given the redistribution of value that creates the relationship 
(Epstein & Ketcham, 2014). In the case of the present study, the consumer-physician 





facilitation, coupled with consumers’ limited knowledge of behavior-shaping learning, 
information processing, and risk factors, completes th  theoretical framework required to 
better understand the impact of DTCA on prescription-seeking behaviors (Arney & 
Lewin, 2013; Spence, 2013). 
 In keeping with the tenets with agency theory, consumer search behavior, at least 
in part, is motivated by perceived risk and consumer ability to acquire pertinent 
information to determine whether a purchase is necessary. In the case of prescription 
drugs, this risk can be defined as a diminished healt  status, illness, injury, or even death 
(Fountain & Reith, 2014; Ross & Kravitz, 2013). Anvari and Amin (2010) provided 
further support for the mediating effects of perceived risk and the increased consumer 
search activity. This phenomenon is known as surrogate consumption theory. The theory 
focuses on those who must or believe that they mustrely on other persons for the 
acquisition- and consumption-related activities that ey desire (Lantos, 2010). Given 
disenfranchisement, a lack of opportunity, or an inab lity to act on their own behalf, 
consumers often engage in surrogate consumption activities. Galbraith’s controversial 
thesis suggested that large corporations seek to manage the demand for their products 
(Goldberg, 2013). Implying that the direct manipulation of consumers’ fuels product 
demand, this thesis provides a potential financial explanation for why DTCA may 
increase demand (Goldberg, 2013). 
The FDA OPDP investigates the applied/theoretical issues relating to the 





drug material (HHS, 2013). In 2011, several experimntal research studies were 
completed by the OPDP. In its 2012 study, the FDA investigated alternative formats for 
presenting the brief summary statement and examined how people read through and 
understand the summary. The study findings showed that adding a serious risk to the 
statement being read did not increase or decrease the overall amount of time taken by the 
participants. The readers’ intention of asking for the prescription also did not change 
under these circumstances. Additionally, individual characteristics had a greater influence 
over reading time compared to characteristics found in the ad statement.  
The FDA (2012) found that the amount of time spent r ading the display page and 
summary were significantly related to the reading speed, age, and health of the reader. 
Finally, there was evidence to support that serious risk information scares possible 
consumers away. Focus groups are also used by the OPDP to gather information as 
related to DTC advertising. The Food and Drug Administration Amendments Act 
(FDAAA) of 2007 has assisted in providing resources for ongoing research and reviews.   
 Alden et al. (1999) offered global consumer culture positioning (GCCP) as an 
alternative approach to brand positioning design for international positioning. The 
researchers examined and contrasted GCCP with local c nsumer culture positioning 
(LCCP) and foreign consumer positioning (FCCP). GCCP involves sharing symbols that 
denote membership in a global consumer segment. These shared symbols can take on 





English language, which is viewed as modernism. English is therefore used for a brand to 
convey this associated meaning.  
 Alden et al. (1999) formulated eight hypotheses. First, all three positioning 
approaches are meaningful in television advertising. Second, the most commonly used 
strategy in television advertising is LCCP. Third, in the United States, GCCP is used less 
frequently in television advertisements. Fourth, in the United States, LCCP is used more 
frequently in television advertisements. Fifth, in television advertisements, more indirect, 
image-oriented approaches are used when GCCP is employed. Sixth, if GCCP is used, 
food products are less often represented, whereas dur ble goods often use this approach. 
Seventh, in television advertising for food, LCCP is used most, but LCCP is used least 
often for durable goods. Eighth, for services, LCCP is more often used. 
 A broad array of Asian and Western cultures (e.g., United States, Germany, 
Korea, India, Thailand, France, and the Netherlands) were selected by Alden et al. (1999) 
to participate. Alden et al. selected random samples of television advertisements from 
each country. A random sample of 20% to 25% of ads was then taken from all collected 
advertisements. A total unduplicated sample of 1,267 remained. Graduate students 
conducted in-depth coding for each of their native countries.  
 The results supported Alden et al.’s (1999) primary hypothesis, with 85% of 
advertisements displaying one of the three positioning options, GCCP, LCCP, or FCCP. 
The researchers’ second hypothesis was also supported, with 59% of advertisements 





Additionally, Chi-square analysis resulted in support f r Alden et al.’s third and fourth 
hypotheses, both of which relating to positioning i the United States. Significance was 
found for types of products that used GCCP, with 56.3% of advertisements using soft-sell 
approaches, which supported Alden et al.’s fifth hypothesis. The other findings also 
support the sixth, seventh, and eighth hypotheses. GCCP was found to be highest (33.3%) 
for high-tech durables, but was only 18.6% of food advertising. In service advertising, 
LCCP was most frequently used often positioning option.  
 Alden et al. (1999) concluded that the then relatively new approach of GCCP may 
be beneficial. For example in economically developing countries, GCCP may work more 
effectively than might LCCP. This study contributed o the existing body of knowledge 
by adding an alternative approach to advertising. The researchers acknowledged several 
limitations in their study, including coding and interpretation of advertisements. The 
study appeared to be generalizable, with the use of ven diverse countries (Alden et al., 
1999).  
Voluntary simplicity (VS), which has evolved in meaning over the years, can be 
defined as a commitment to the nonmaterial aspects of life or living a simpler life. In 
practice, a person minimizes consumption of material goods and may even carry over to 
working less (Ekstrom & Glans, 2012).  
 Shaw and Newholm (2002) examined the differences between ethical 
consumption behaviors and voluntary simplified behaviors, and presented findings from 





consumer’s choice to simplify individual consumption behavior. In comparison, ethical 
consumers restrain from consumption because of some ethical concern, such as taking 
public transportation rather than driving a fuel-inefficient car. Shaw and Newholm (2002) 
stated that “a fine distinction cannot be made betwe n the extent and nature of 
consumption in affluent consumer societies” (p. 169). Therefore, consumers engage in 
the following behavior approaches: downshifting, voluntary simplicity, and sustainable 
levels of consumption. Shaw and Newholm described downshifting as a type of VS; 
however, downshifters seek to maximum quality time ov r other motivations, such as 
income.  
Shaw and Newholm’s (2002) premise was that VS may be demonstrated among 
consumers whose behavior includes some ethical consideration of the environmental and 
social impact of their consumption choices (p. 180). The two qualitative studies examined 
by Shaw and Newholm were conducted in the United Kingdom between 1996 and 1999. 
One study consisted of 15 ethical consumers forming two focus groups. The other study 
involved 16 case studies of ethical consumers. The respondents’ attitudes in relationship 
to three consumption areas (diet, car or non-car travel, and use of secondhand products) 
were discussed. Shaw and Newholm reported that, in both studies, the majority of 
respondents had modified their diets for various ethical reasons, including treatment of 
animals and environmental concerns. Dietary changes included becoming a vegetarian, 
reducing meat purchases, only buying free-range anim l products, or increasing 





Environmental concerns were one of the issues associ ted with choices made 
relative to transportation. Although some respondents owned cars, they indicated a lack 
of or problems with public transportation. Shaw and Newholm (2002) cited that some 
respondents decided to live in areas in which employment and amenities were in walking 
distance to address the transportation concern. The use of secondhand items was another 
choice made by respondents. One respondent reported that it was more economical and 
efficient to purchase used products or items, including homes, clothes, and appliances. 
The authors concluded that the findings “suggest[ed] hat consumers who start from the 
premise that ethical issues are applicable to theirconsumption also consider the extent of 
that consumption” (Shaw & Newholm, 2002, p. 180).   
Finally, Ahn et al. (2014) and Park, Ju, and Kim (2014) provided empirical 
evidence of the positive association between DTCA and consumer perceptions of the 
prevalence and risks of depression. By playing a role in creating social reality of diseases 
and medicine, the social cognitive effects of DTCA are considered far-reaching and 
influencing to pharmaceutical firm marketing strategy. This effect further raises complex 
ethical concerns. Although the study was limited to print advertisements for 
antidepressants, it provided support for the broader exploration of this phenomenon in 
general DTCA. The present study sought to contribute to the overall body of knowledge 






Review of Research Methods and Differing Methodologies  
The approach to research designs can be qualitative, quantitative, or a 
combination of both. There are many approaches to each design; some of the more 
frequently used include field research, experimental, evaluation, and survey. Singleton, 
Singleton, and Straits (2010) defined field research as directly observing others in a 
natural setting. This form of observation may extend over a period of time and may 
include interaction. Case studies are one of two approaches of field research. The other 
type of study is known as ethnographies. According to Singleton et al., most field 
research involves a case study in that a single unit analysis is examined. In comparison, 
ethnographies usually describe a culture based uponlong field investigation. Singleton et 
al. stated that researchers select this type of resea ch to obtain an insider’s viewpoint. In 
addition to observing the unit of analysis or social phenomenon, the researcher can better 
understand substance of views within a setting.  
 Like other research approaches, there are advantages and disadvantages to 
using field research. Field research can be less cotly in comparison to other methods 
because it can be conducted nearby; however, this type of research tends to be labor-
intensive. Other disadvantages to using field research include replication difficulty and 
issues involving generalizability. In situations where the researcher has limited 
knowledge about the subject or ethical challenges restrict other research approaches, field 





Experimental research is another approach that is described as an empirical 
investigation that attempts to describe a causal explanation. In a true experimental 
research design, the participants are assigned randomly to either an experimental group or 
a control group (Marczyk, Dematteo, & Festinger, 2010). Additionally, according to 
Singleton et al. (2010), this type of research entails he manipulation of an independent 
variable while controlling exposure or contact to oher events. Control of extraneous 
variables is crucial due to the threat to internal validity.   
Singleton et al. (2010) also defined evaluation research as a type of social science 
research that focuses on analyzing social programs and policies. These social programs 
are primarily instituted by government entities (federal, state, or local). Evaluation 
research uses the same types of methods and addresses many of the same issues as other 
research methods; therefore, the designs and validity ( nternal and external) issues are 
similar to those discussed under other methods. The primary distinction is that evaluation 
research applies research to social context. Monette, Sullivan, and DeJong (2013) 
described three reasons for conducting evaluation research: to test hypotheses, to support 
evidence-based practice, and for administrative purposes.   
This present study used survey research. Like the other approaches, there are 
many advantages and disadvantages to this approach. M rczyk et al. (2010) described 
survey studies as a method in which the researcher asks a large number of people 
questions. These questions can address attitudes, opinions, or specific behaviors. The 





may be made to find a relationship between reported behaviors/opinions and the 
respondents’ characteristics. Similarly Singleton et al. (2010) explained that the 
researcher examines the relationships among the measures once information is gathered 
from the survey. Additionally, survey research design  are divided into two categories: 
cross-sectional and longitudinal.  
The cross-sectional design is one in which data are coll cted at one point in time 
from a sample of respondents selected to represent th  target population. According to 
Singleton et al. (2010), this one point in time means that the data are collected in the 
shortest feasible amount of time. The cross-sectional design has two variations: 
contextual design and social network design. Both types of designs can be used to study 
individuals within the same social context; however, contextual designs involve sample 
cases within a particular group to describe characte istics. In comparison, social network 
designs, which often require the researcher to interview every person in the study, are 
used to examine the relationship among people or other target performers. Longitudinal 
designs are studies in which data are collected at more than one point in time. 
Researchers using this type of design may ask the sam  questions to every individual or 
independently select samples from the same population. When repeated surveys are 
administered to independent samples of the same population, this type of longitudinal 
design is known as a trend study. The other type of study in which the same individuals 
are surveyed more than once is known as a panel study. The cross-sectional design is the 





Using the survey approach, researchers often strive to make inferences about a 
whole (known as the population) from observations taken from a sample of the whole 
(Singleton et al., 2010). Because it is often impossible to observe all actions or events, 
sampling may be a solution; a sample that is represntative (characteristics are close to 
those of the target group) of the target population is used. Typically, sampling reduces 
time and cost of a study. Once a researcher has selected the unit of analysis, the number 
of units and the method upon which the units will be selected must be decided. According 
to Singleton et al. (2010), the first step in sampling is defining the population of interest, 
which is a two-step process. The target population, which is the population to which 
results are to be generalized, must be identified. This process can be performed by the 
researcher by establishing criteria to determine which cases to include and exclude in the 
population. Geographic boundary and time frame are two characteristics identified by 
Singleton et al. that can assist in defining the researcher’s target population.   
The second step is making the target population operational, which requires 
constructing a sampling frame. A sampling frame for a survey approach often entails 
obtaining a listing of the population or subgroups of the population. Next, a sampling 
design is developed. This design establishes how cases will be selected for observation 
and falls into two categories: probability sampling and nonprobability sampling.   
In probability sampling, all cases have a chance of being randomly selected from 
a population. In contrast, nonprobability sampling does not have this known probability 





types of probability sampling: random selection, simple random sampling, stratified 
random sampling, cluster sampling, and systematic smpling. In random selection, each 
case within a population has an equal chance for selection. According to Singleton et al. 
(2010), mechanical or electronic aids should be used in this process. Similarly, in simple 
random sampling, each case has an equal chance of selection, but this procedure refers to 
combinations of cases. In the third type of probability sampling, stratified random 
sampling, a subdivision is made to the population frst and then simple random samples 
are selected from each segment. These subdivisions are mutually exclusive and this 
procedure can increase sample precision.  
The fourth type of sampling, cluster, also involves dividing the population; 
however this breakdown into clusters is according to natural areas or groupings. Random 
sampling then occurs from the clusters. Singleton e al. (2010) offered several examples 
of clusters to include colleges, churches, states, nd cities. Clustering is performed most 
often to reduce the expenses associated with data collection. Another type of probability 
sampling is systematic sampling in which a researcher ooses a number, then selects a 
case with that number from a complete list of the population, such as every 10th case 
(Singleton et al., 2010).   
There are several modes of survey instrumentation: face-to-face interviews, 
telephone interviews, self-administered questionnaires, or a combination of these 
approaches. The overall interviewing technique has t e advantage of allowing the 





clarify answers given by the respondents. One possible d sadvantage to interviewing is 
the required training that is often needed for the int rviewers. Interviewing can be done in 
person (face to face) or over the telephone. Face-to-face interviews typically have a high 
response rate, allows for the use of visual aids an the making of unobtrusive 
observations. However, one disadvantage to face-to-face interviewing is the cost. Costs 
may be reduced by using telephone interviews; however, establishing rapport with 
respondents is often more difficult. Additionally, complex questions may not be suitable 
for telephone interviews. Another mode is self-administered questionnaires via the mail 
or electronic means, such as the Internet. This appro ch is often the least costly of all 
approaches and has the advantage of allowing the respondents to complete the item at 
their convenience (Singleton et al., 2010). The present study used an online survey 
approach.   
Summary 
In this chapter, the theoretical framework was discus ed. This theoretical 
framework included social cognitive theory, choice, and agency theory as related to 
advertising. Global consumer culture positioning was also discussed in this review. 
Research does exist in the overall advertising field of study; however, research specific to 
DTCA in comparison is limited. DTCA is a particular type of advertising; its possible 
risks may be associated with the use of prescription medications. Several studies have 
been conducted by the FDA, with most being experimental in nature. A 2004 study by 





frequently in the review of literature. Like the 2004 FDA research, the present study used 
the survey method. Other research discussed in this literature review included a content 
analysis based on Bandura’s (2001) social cognitive theory. The purpose of the Welch 
Cline and Young (2004) study was to identify features of DTCA that could function as 
modeling.   
Relevant literature covering the history of governme tal regulation of the 
production and sale of prescription medications, the potential supply and demand side 
incentives, as well as the behavioral and agent aspect  of consumer drug seeking were 
reviewed in developing the theoretical framework. As a comprehensive consideration of 
the phenomena associated with DTCA, this literature review and theoretical framework 
provided a foundation and balanced understanding of the actors and issues pertinent to 
understanding the complexities of suggested associations. This framework established the 
premise for the present study and served as the basis for the two specific hypotheses that 
were tested. Chapter 3 contains an explanation of how t e study was designed. Chapter 4 
includes a discussion about the outcomes of the study. Chapter 5 includes discussion, 







Chapter 3: Research Method 
Introduction 
 The purpose of this study was to determine the association between DTCA and 
health care-seeking behaviors and to explore patient p rspectives on their overall health 
care experience. Singleton et al. (2010) defined research, specifically social research, as a 
process of first formulating questions and then seeking answers to the questions about a 
person’s social environment or surroundings. Both fu ure producers of research and 
consumers of research findings benefit from understanding research methods. From the 
consumer perspective, research findings are displayed on a daily basis in everyday life. 
One example of such use of research is in advertising, in which results from studies and 
other forms of research are introduced to encourage the viewer to purchase a specific 
product or service. At times, it can be difficult to decipher which advertisements are 
presenting misleading information. Therefore, the consumer must listen and understand 
the methods that are used in the overall research process.  
 Generally, the approaches to research are either qualitative or quantitative. 
Research designs can also use a combination of both (qualitative and quantitative) 
approaches. Additionally, there can be a variety of methods or strategies used with either 
approach (Singleton et al., 2010). This section provides details on the research design, 
research questions and hypotheses, data collection, data analysis, and theoretical 






 This research study included two types of variables. The independent variables 
were patient exposure to advertising as measured by ight questions (see Table 2), 
sociodemographic characteristics (i.e., age, gender, income, and ethnicity), health status, 
and education. The dependent variable, health care-seeking behaviors, were comprised of 
two variables: physician office visits as measured by four questions (see Table 2) and 
asking for a prescription as measured by four questions (see Table 2).  
Research Hypotheses 
 The two hypotheses of this study posited that patient exposure to DTCA is 
associated with physician office visits. Specifically, Hypothesis 1 related to physician 
office visits and exposure to DTCA:  
H10: There is no relationship between patient exposure to DTCA and subsequent 
physician office visits. 
H1a: There is a direct association between patient exposure to DTCA and 
subsequent physician office visits. 
Hypothesis 2 related to requests for a specific prescription medication and exposure to 
DTCA: 
H20: There is no relationship between patient exposure to DTCA and a patient 
asking subsequently for a corresponding prescription drug. 
H2a: There is a direct association between patient exposure to DTCA and a 





Research Design and Approach 
 In this study, I used a quantitative approach. There are pros and cons to either 
(qualitative or quantitative) research design. Denzin and Lincoln (2011) defined 
qualitative research as an approach in which the res archer studies factors or events in 
their natural settings. The data or material can be coll cted through a variety of methods, 
including case studies, interviews, observations, historical account, or personal 
experience. Creswell (2012) presented a list of the characteristics of qualitative research: 
• Natural setting as source of data (the environment in which the observed 
event occurs); 
• Researcher as key instrument of data collection 
• Data collected as words or pictures 
• Outcome as process rather than product 
• Analysis of data inductively, attention to particulars 
• Focus on participants’ perspectives, their meaning; 
• Use of expressive language 
• Persuasion by reason. (Creswell, 2012, p. 44)    
 Quantitative research was described by Marczyk et al. (2010) as involving studies 
that use statistical analyses in the process of obtaining findings. Quantitative methods can 
also be defined as focusing on strict quantifiable data. In quantitative research, large-scale 
sampling procedures are most often used, as well as stati tical tests to study averages and 





back to the natural sciences, whereas the qualitative research approach is more related 
historically to the human or social sciences. Quantit tive research is often represented by 
the following characteristics: deductive in nature, is theory-driven, attempts to understand 
laws and causes, and is outcome-oriented. In contrast, qualitative research is inductive, 
theory-generating, seeks meanings, and is discovery-oriented.   
 A quantitative survey was used to collect data from participants in the present 
study. Specifically, I used the 2004 FDA survey instrument in this study. Marczyk et al. 
(2005) claimed that researchers use survey studies to a k questions to a large number of 
people. These questions can be used to investigate attitudes, opinions, or specific 
behaviors. The findings from surveys may be limited to escribing responses, but an 
attempt may be made to find a relationship between r ported behaviors/opinions and the 
respondents’ characteristics. Similarly, Singleton (2010) stated that relationships among 
the measure are examined once people answer questions, which is the basic idea of a 
survey. Reasons for using this approach vary; however, Fowler (2014) stated that surveys 
may be the only means of getting information that is easy, quick, and inexpensive.  The 
budget of researchers vary and surveys may allow for quick collection of data that is also 
less expensive.  
 Surveys are unique from other means of collecting data. Singleton et al. (2010) 
described three features of survey research. First, many surveys consist of a large number 
of respondents. To represent the target population, the respondents are selected through 





of the process of asking prearranged questions. These interviews may be structured, 
unstructured, or semistructured. The optimal structured interview contains specific 
objectives with prearranged questions. Comparatively, in an unstructured interview, the 
interviewer may make adaptations. The third feature of surveys consists of the 
numerically coding and analyzing of respondents’ anwers.  
 Survey research methods have numerous advantages and dis dvantages. One 
advantage is that surveys can be an efficient means of gathering data. This approach can 
address multiple research questions within one survey. Another advantage is the lower 
costs of obtaining data, which can be even less when using secondary analysis of survey 
data collected from professional or other resources. There are also several limitations to 
survey research. Surveys are less adaptable and systematic measurement error may occur 
(Singleton et al., 2010).     
Setting and Sample 
The survey for this study was available to participants via the university website 
and SurveyMonkey. Inclusion criteria for this study consisted of adult college students. A 
diverse population of people worldwide was represented by this online university and 
SurveyMonkey. According to the U.S. Department of Education (2013), the actual 
number of college students in 2010 was 21 million and, for the fall of 2013, it was 
projected to be 21.8 million. Published sample sizetables, online sample calculators, and 
formulas are some of the tools that can be used to determine sample size of a study. 





all factors that have an impact on the needed sample size for a study (Cottrell & 
McKenzie, 2010).  
In this study, I used Cochran’s (1963) formula for calculating sample size: 
n = Z2(pq)/e2 
where the sample size is n, Z is the appropriate Z score for a confidence interval, p 
represents an estimate of the proportion of the attribu e in the population, q is 1 - p, and e 
is the margin of error or level of precision. A conservative estimate was used, whereas 
the value of p was 0.5, given the unknown variability of the attribute (health care-seeking 
behaviors), and the margin of error, e, was 10%. The confidence interval of 95% was 
used for this study. Using this equation and the projected number of college students 
(21.8 million), the suggested minimum sample was 96 participants.    
Given the small sample size suggested by Cochran’s (1963) formula, a power 
analysis was conducted. Because the alpha level is the probability of incorrectly rejecting 
the null hypothesis (Type I error), the alpha level is the chance of incorrectly inferring a 
difference where none exists. Beta is the probability of incorrectly rejecting the null 
hypothesis (Type II error), or incorrectly inferring o difference where one actually 
exists. The power of a test is measured by 1 – beta and therefore relates to Type II errors.  
 Decreasing the alpha level increases the probability of a Type II error by 
decreasing power but increases the confidence in the results by decreasing the probability 
of a Type I error. Conversely, increasing the alpha level increases the potential for a Type 





II error by increasing power. Because the standard eviation and mean for the population 
are unknown, a conservative alpha level of 0.05, medium effect size of 0.30, and power 
of 0.95 were used to ensure adequate power and confidence in the results. Using this 
information, a power analysis and sample size-determining statistical program called 
G*Power version 3.1.9.2 (Faul, Erdfelder, Buchner &, Lang, 2009; Jones & Lentz, 2013) 
determined a minimum sample size of 177 to provide statistical power of 0.95. This more 
conservative required sample size was used for this s udy. 
Instrumentation and Materials 
 The survey instrument used in the present study was ad pted from a 2004 study 
by the FDA. Report findings from the FDA study, thesurvey, and the dataset were all 
available to the public on the FDA.gov website. The FDA survey was conducted 
nationally via telephone in 1999 and 2002. These previous surveys were basically 
identical, with only slight revisions made for clarification purposes and the inclusion of 
health insurance questions. The present study used only 24 questions (relevant to study 
variables) from the patient survey, the original of which contained 65 questions. The 
survey was divided into the following sections:  
1. Survey inclusion: Participants must be 18 or older and have visited a doctor, 
nurse practitioner, or a physician’s assistant for a health condition or concern 
of his or her own within the last year. This visit was for a concern of the 
patient’s own, not for a child or parent or someone els .   





3. Interaction with doctor: Patient type of visit and conversation.  
4. Attitude/questions about prescription drug advertising: Overall attitudes about 
DTCA. 
5. Demographic Information: Education, ethnic group, health insurance, and so 
on.   
The survey instrument was adapted for the present study. The original study was 
conducted via telephone; therefore, adaptations were made to conduct the survey online. 
This change allowed participants to select from a list of answer choices online compared, 
to responding verbally to questions posed over the telephone. The majority of the survey 
questions were measured using Likert scales. Table 2 provides a “crosswalk” of the 








Study Variables and Corresponding Survey Questions 
Study variables Survey question* 
Patient exposure Q3. In the last year, do you recall seeing or hearing any 
advertisements for prescription drugs? (Recall DTCA)  Yes No 
Q4. Have you seen or heard any ads for prescription drugs in any 
of the following ways: (Forms of DTCA) 
 a. On television 
 b. On the radio 
 c. In a magazine 
 d. In a newspaper 
 e. On the Internet 
 f.    In a letter, flyer, or announcement you got in the mail 
 g. On an outdoor billboard 
 h.   In a grocery store or pharmacy  
 i.   Anywhere else? (please specify) 






Study variables Survey question 
Patient exposure Q5. In the last year, how many different prescription drugs do you 
recall seeing advertised in any form? (Number of DTCA) 
 None One  Two  Three 
 Four Five  Six  Seven 
 Eight Nine  Ten  More than ten 
Q6. Thinking about the ads you have seen both in print and on 
television, has an advertisement for a prescription drug ever caused 
you to look for more information, for example, about the drug or 
about your health?  (Look for more DTCA information)  Yes No
  
Q7. What information did you look for? (Type of DTCA 
information) 
Side effects 
Interactions with other drugs/medicines  
Dangers of the drug 
Cost of the drug  
Other__________ 





Study variables Survey question 
Patient exposure 
 
Q8. Has an advertisement for a prescription drug ever caused you 
to ask a doctor about a medical condition or illness of your own that 
you had not talked to a doctor about before?  (Ask doctor about 
medical condition)   Yes   No 
Q15. I like seeing advertisements for prescription drugs. (Like 
seeing DTCA) 
Agree strongly  
Agree somewhat  
Neither agree nor disagree  
Disagree somewhat  
Disagree strongly  
Q16. Advertisements for prescription drugs help me make better 
decisions about my health. (DTCA help in decision making) 
Agree strongly  
Agree somewhat  
Neither agree nor disagree  
Disagree somewhat  
Disagree strongly  





Study variables Survey question 
Physician office visits Q1. How long has it been sice the last time you saw a doctor, a 
nurse practitioner, or a physician’s assistant where you talked about 
a health condition or concern of your own, not for a child or parent 
or someone else?  (Last Visit)  
Within the last week 
1 to 4 weeks ago   
5 weeks to 3 months ago   
4 to 6 months ago 
7 to 11 months ago   
1 year ago   
More than 1 year ago   
Never 
Q2. Was this a routine visit, such as a checkup or physical? 
(Routine visit) Yes No Don’t know 
Q9.  At any of the visits to your doctor, did you talk about a 
prescription drug? (Talk about prescription)  Yes No 






Study variables Survey question 
Physician office visits Q14. Overall, how would you rate your interaction with your doctor 
at this visit? (Interaction with doctor) 
Excellent  
Good  
Only fair  
Poor  
Asking for a 
prescription 
Q10. Did you go to this visit expecting your doctor t  prescribe a 
drug for you? (Expect Prescription) Yes   No 
Q11. At that visit, did you ask whether there might be a prescription 
drug to treat you? (Ask about prescription)  
 Yes   No 
Q12. Did you mention an advertisement you saw or hea d for a drug 
or bring information about the advertised drug with you? (Mention 
DTCA) 
 Yes, I mentioned an ad I saw or heard  
 Yes, I brought something about the drug with me  
 Yes, both  
 No 





Study variables Survey question 
Asking for a 
prescription 
Q13. Did your doctor do one or more of the following: (Doctor 
recommendation)  [Select all that apply] 
 Give you the prescription drug you asked about  
 Not give you the prescription drug you asked about  
 Recommend a different prescription drug  
 Recommend an over-the-counter drug  
 Recommend no drug  
 Recommend you make changes in behavior or lifestyl 
 Something else (specify)   
Sociodemographics Q17. Overall, would you say your health is: (Health Status) 
 Excellent Very good Good  
 Fair  Poor  
Q18. How many hours in a typical week do you use the Internet or 
World Wide Web at home and at work?  (Use of Internet or World 
Wide Web). 
 ___________________ Do not have a computer. 
Q19. Gender (Gender): Male Female  






Study variables Survey question 
Sociodemographics Q20. What is your marital status? (Marital Status) 
Married  Single  Widowed  
Divorced  Separated 
Q21. What is the last grade of school that you completed? 
(Education) 
Grade school or less Some high school  
Completed high school Some college  
Completed college Graduate school or more  
Other beyond high school (business, technical, etc.)
Q22. Are you of Hispanic, Latino, or Spanish origin? (Hispanic 
origin) 
No, not of Hispanic, Latino, or Spanish origin 
Yes, Mexican, Mexican American, Chicano 
Yes, Puerto Rican  
Yes, Cuban 
Yes, another Hispanic, Latino, or Spanish origin – Please state 
origin, for example Argentinean, Colombian, Dominican, 
Nicaraguan, Salvadoran, and so on _________________. 








Study variables Survey question 
Sociodemographics Q23. What is your race? (Race) Sel ct one or more 
White  Black, African American, or Negro 
American Indian or Alaska Native Asian Indian 
Chinese  Filipino  Japanese 
Korean  Vietnamese 
Other Asian – (For example Laotian, Thai, Pakistani,  
Cambodian, and so on) _______________________. 
Native Hawaiian  Guamanian or Chamorro 
Samoan  Other race __________________. 
 Q24. What year were you born? (Age) _________ 
 
Note. An abbreviation for each question is presented in parentheses. 
 
 
Reliability and Validity 
Validity refers to the extent to which an instrument measures what it is purported 
to measure (Leedy & Ormrod, 2013). There are no statistical tests for validity, but an 
instrument is considered valid when the researcher reaches the opinion that the 
instrument is measuring what it was designed to measur . There are several types of 
validity (criterion, content, and construct). Criteon validity checks the performance of 
an instrument to outcomes that are already held to be valid. Content validity considers 
where the instruments items are logically associated with the phenomenon to be 





investigated whenever no criterion or universe of content is accepted as entirely adequate 
to define the quality to be measured” (p. 282). In addition to FDA assurances of survey 
validity from their use of the instrument for other studies, the questions or variables were 
compared to other drug advertising research in peer-reviewed journals as an assessment 
of content and construct validity (Bhutada et al., 2013). Because the questions were direct 
and were not intended to measure complex psychometric concepts such as personality, 
trust, mental capacity, or quality of life, face validity was determined by comparing the 
question to the applicable operational definition t ensure congruency.   
Leedy and Ormrod (2013) described reliability as referring to the extent to which 
an instrument produces consistent results on repeatd tests. Reliability of an instrument is 
closely associated with its validity; however, an instrument cannot be valid unless it is 
reliable (Tavakol & Dennick, 2011).  
The present study used Cronbach’s alpha to measure reliability with the following 
formula:  
α = Nρ / [1 + ρ(N - 1)] 
where N is equal to the number of items and ρ is equal to the mean inter-item correlation. 
This calculation is expressed between 0 and 1 and is a measure of the internal consistency 
of a test/scale. No pilot testing was performed; however, researchers who developed, 
validated, and used the survey instrument in the 2004 FDA study reported a reliability 






Approval from the institution review board (IRB) was obtained prior to uploading 
the study to the participant pool and SurveyMonkey. Once uploaded and approved, a 
mass e-mail informing the college community of the study, as well as a link to the survey, 
was distributed by the college and SurveyMonkey. Participants were able to access the 
survey anonymously. Based upon the 15-minute collection time reported by the FDA 
(HHS, 2004), it was anticipated that participants would take approximately 5–8 minutes 
to complete this online survey. The survey was made available for several weeks to reach 
the target sample. A total of 235 participants completed the survey. 
Data Analysis 
The present study was quantitative and the data were analyzed using descriptive 
statistics and analyses of variance (ANOVAs), which were employed to test the 
hypotheses of this study. Descriptive statistics are used in research to summarize data and 
numerically describe variables. Inferential statistics, in contrast, are used to make an 
assumption about a population based upon the sample (McNabb, 2013). 
With each analysis, statistical significance and predictive value were assessed, as 
applicable. A two-step technique was used, as applicable. First, the independent variables 
and the dependent variable were loaded into an ANOVA to determine the predictive 
power of the equation. Next, the applicable sociodemographic variable(s) were loaded 
into an equation with the dependent variable to assess the impact of the variable(s). 





predictive value of DTCA. Statistical Package for the Social Sciences (SPSS), Version 
21, was used for all data analyses. Given that multiple ests would be run on the data, the 
Bonferroni correction was used to control the family-wise error rate. Although considered 
conservative, this correction seeks to maintain an acceptable probability of false positives 
and false negatives by adjusting the p value to a level more stringent than 0.05. An 
ANOVA can be used to determine if the considered means are different and the 
Bonferroni correction helps to identify specifically which means are different. Using 
SPSS Version 21, statistical significance was assessed at the p < 0.025 level, given the 
more stringent level required by the Bonferroni correction. This value was derived by 
dividing the traditional alpha level of 0.05 by the number of hypotheses being tested 
(0.05/2=0.025; Jiang, Barmada, Cooper, & Becich, 2011; Patel, Chen, Kodama, Ioannidis 
& Butte, 2012; Pollak, Jones, Castillo, Bosse, & MacKenzie, 2010). 
The 2004 FDA study sought to assess patient awareness of and opinions about 
DTCA efforts, and patients’ processes for obtaining more information and asking 
questions. As a largely descriptive study, few inferential assertions were included in the 
original study. The present study used the raw dataob ined from the FDA survey for 
comparative purposes. A sociodemographic profile of the survey respondents for the 
1999 and 2002 surveys is presented in Table 3. The highest proportion of respondents 
were between 35 and 54 years of age (43%/40%), female (65%/65%), White/Caucasian 
(77%/79%), with incomes of less than $50,000 (53%/53 ), completed college or more 





excellent/very good (56%/51%). The stark sociodemographic similarities between the 
two surveys and society at large support the reliability of the employed sampling 
techniques. The present study had 235 respondents, with characteristics shown in Table 
4. Chapter 4 provides more details regarding study respondents.   
Theoretical Model 
 This research used a theoretical framework consisti g of social learning theory, 
information integration theory, and prospect theory t  examine consumer behavior as it 
relates to DTCA of prescription drugs. The 2004 study by Welch Cline & Young 
conducted a content analysis based on Bandura’s social learning theory. The purpose of 
the Welch Cline & Young study was to identify features of DTCA that may function as 
modeling. Visual cues were examined as vicarious motivat rs. Bandura’s social learning 
theory describes that when a behavior is observed th  possible observed rewards can 
become motivators. Specifically, in DTCA cures, happy or healthy product users are 
motivators. Welch Cline & Young concluded that change in health care behavior might 
be triggered by DTCA. Consumers are often exposed to visual models with positive 
features, such being active and friendly. 
 The fundamental concept of integration theory is that he way a person thinks or 
behaves depends on multiple stimuli acting in cooperation with one another. Integration 
function combines the transformed psychological stimuli into an implicit response, which 
is then externalized using the response function. A person uses simple algebraic rules on 







Sociodemographics of FDA (HHS, 2004) Survey Respondents 
Respondents 
1999 (N = 960) 2002 (N = 944) 
% n % n 
Age 
18–24 7 69 7 65 
25–34 17 155 15 140 
35–44 23 218 18 171 
45–54 20 196 22 208 
55–64 14 131 17 164 
65+ 20 191 21 196 
Gender 
Male 35 334 35 327 
Female 65 626 65 616 
 








1999 (N = 960) 2002 (N = 944) 
% n % n 
Ethnicity (multiple responses permitted) 
American Indian/Alaska Native 4 34 4 34 
Asian/Pacific Islander 3 25 2 23 
Black/African American 12 116 10 99 
Hispanic/Latino 4 43 4 36 
White (Caucasian) 77 742 79 747 
Income 
Less than $20,000 20 189 19 185 
$20,000–less than $34,999 17 162 17 161 
$35,000–less than $49,999 16 153 17 158 
$50,000–less than $74,999 14 132 18 166 
$75,000+ 16 155 20 191 
Education 
Completed high school or less 36 341 39 366 
Some college 24 226 21 201 
Completed college or more 40 388 40 375 
Marital status 
Married 56 534 58 550 
 






1999 (N = 960) 2002 (N = 944) 
% n % n 
Single 22 212 21 197 
Widowed 10 100 9 83 
Divorced 9 84 10 95 
Separated 3 27 2 16 
Health status 
Excellent/very good 56 536 51 481 
Good/fair/poor 44 421 49 463 
 
 Prospect theory similarly examines how one makes decisions. Prospect theory 
attempts to describe decisions that are made among alternatives where risk is involved 
(Nickerson, 2012). The knowledge and understanding required to make safe and 
appropriate medication decisions is so advanced that the general public must rely on the 
expertise of physicians to determine the appropriateness and authority to obtain and 
consume some high-risk medications (Pardun, 2014). In agency theory, this agency 
relationship moderates the conditioning, learning, tegration of information, and 
prospect decisions of the average person. Within this theoretical model, it is suggested 
that patients, regardless of their sociodemographic rofile, seek to engage their agent in 
their desire to be considered for or obtain prescription medications. 
 To summarize the theoretical model, social learning theory considers 





environmental influence on patient behavior. Information integration theory considers the 
interaction of multiple stimuli on behavior. In the present study, DTCA is considered a 
stimulus affecting patient behavior. Prospect theory suggests that individuals engage in 
beneficial decision making, ensuring that gains are greater than losses. In this study, 
DTCA helped individuals draw conclusions about gains a d losses in terms of their 
health. All these theories about individual behavior must be considered within the context 
of agency theory because only doctors can prescribe p escription medications and 
patients are generally less educated about health care than their doctors. Therefore, 
doctors act in an agent role on behalf of their patient.   
Protection of Participants 
The university IRB oversees all proposals to maintain p rticipant rights and 
protections. The IRB ensured that the methods of data collection for this study presented 
minimal risk to participants, complied with ethical principles, and met confidentiality 
requirements. Participation in this study was voluntary. Participants had the right to 
withdraw from the study at any time during the study process. Additionally, participants 
had the right to ask questions during the survey process or afterwards. No incentives were 
given for participation in this study. Approval from the IRB was obtained before data 
collection began.   
Summary 
 The purpose of this study was to determine the association between DTCA and 





patients’ overall health care experience. This research used a theoretical framework 
consisting of social learning theory, information integration theory, and prospect theory 
to examine consumer behavior as it related to DTCA of prescription drugs. This research 
study included two types of variables. The independent variables were patient exposure 
to advertising, sociodemographic characteristics (i.e., age, gender, income, and ethnicity), 
health status, and education. The dependent variable, health care-seeking behaviors, was 
the summary of two variables: physician office visits and asking for a prescription. The 
two research hypotheses of this study posited that patient exposure to DTCA was 
associated with physician office visits.   
 This study uses a quantitative approach however; th e are pros and cons to either 
design method. The survey instrument that was used was taken from the 2004 study 
conducted by the FDA. This instrument was made avail ble to participants in the present 
study via the university website and SurveyMonkey. Approximately 5,000 individuals 
were included in the overall university participant pool. Inclusion criteria for this study 
consisted of adult students who had seen a doctor, a nurse practitioner, or a physician’s 
assistant for a condition or concern of his or her own in the past year. A diverse 
population of people worldwide was represented in this online university. Data were 
analyzed using descriptive statistics and ANOVAs, which were employed to test the 
hypotheses of this study. The Bonferroni correction was used to control the family-wise 
Type I error rate. With each analysis, statistical significance and predictive value were 





university IRB was obtained prior to the data collection process. The results of the 








Chapter 4: Results 
Introduction 
 The purpose of this study was to determine the association between DTCA and 
health care-seeking behaviors and to explore patient p rspectives on patients’ overall 
health care experience. Two research questions acted s a catalyst for this study:  
1. What is the relationship between direct-to-consumer advertising (DTCA) 
and physician office visits? 
2. What is the relationship between direct-to-consumer advertising (DTCA) 
and patients asking for a prescription?  
These questions were researched through two hypotheses. Hypothesis 1 related to 
physician office visits and exposure to DTCA: 
H10: There is no relationship between patient exposure to DTCA and subsequent 
physician office visits. 
H1a: There is a direct association between patient exposure to DTCA and 
subsequent physician office visits. 
Hypothesis 2 related to requests for a specific prescription medication and exposure to 
DTCA: 
H20: There is no relationship between patient exposure to DTCA and a patient 
asking subsequently for a corresponding prescription drug. 
H2a: There is a direct association between patient exposure to DTCA and a 





The data were collected via an online survey and were analyzed with the 
statistical program SPSS, Version 21. This chapter includes a presentation of the 
collected data, an analysis of the findings, and summarized results. 
Data Collection 
Data were collected via an online survey posted on two survey websites, a 
university website participant pool and on SurveyMonkey. The collected data were 
analyzed with SPSS using ANOVAs, which were employed to test the hypotheses of this 
study. The statistical significance and predictive value were assessed, as applicable. 
After receiving approval from the IRB, the survey was uploaded to the university 
website for access by an online participant pool. A mass e-mail list of newly posted 
studies for that month was sent to inform the college community. Interested participants 
were then able to register (if needed) to use the si e and then access the anonymous 
survey instrument via this online participant pool. The survey was made available for 4 
weeks with few participants (five). To reach the target sample of 96 participants, the 
survey was made available for an additional 3 months, for a total of 132 days. Still, only 
30 participants had accessed and taken the survey via the online participant pool. To 
obtain additional participants, I engaged the servic s of SurveyMonkey to assist in 
obtaining additional participants who met the criteria of at least 18 years of age and a 
current student.  
This study remained a focus of an academic community; therefore, the criteria 





number of college students in 2010 was 21 million and, for the fall of 2013, was 
projected to be 21.8 million. Maintaining a confidenc  level of 95% and a confidence 
interval of 10, the sample size remained at 96 participants. Prior approval was obtained 
from the IRB to make this procedural change of posting on SurveyMonkey. 
SurveyMonkey participants received the same invitation/consent forms and were offered 
the survey to complete online. The survey consisted of 24 questions (eight questions used 
to assess patient exposure, four questions for physician office visits, four questions for 
asking for a prescription, and eight sociodemographic questions). There were 205 
respondents via SurveyMonkey. Data from the participant pool and SurveyMonkey were 
combined and analyzed for a total of 235 participants. The sociodemographic profile of 
participants in this survey was also compared to the profile of the participants in the FDA 
(HHS, 2004) 2002 survey. To minimize the number of deleted cases in each analysis, 
pairwise deletion was used to address missing completely at random data (Baraldi & 
Enders, 2010).    
Descriptive Statistics 
 The survey was opened for volunteers for approximately 8 months. A total of 89 
male students (38%) and 144 female students (62%) partici ated. The 2002 FDA survey, 
although having a larger sample size (944), had a similar composition of 35% male 
participants and 65% female participants, as shown in Table 4. All participants were over 
18-years-old, with 90 (38.3%) between 18- and 24-years-old, 59 (25.1%) between the 





of 45 and 54, and 13 (5.6%) over 55 years of age. By comparison, there were a larger 
number of older respondents in the original FDA (HHS, 2004) survey, with 58% being 
over the age of 45. The ethnicities of respondents in both the present study and the FDA 
survey were similar: 79% were White/Caucasian American for the FDA survey and 
80.5% for this survey. However, respondents to the original FDA survey showed a higher 
percentage of being married at 58%, compared to 28% in this study. Table 3 represents 
the sociodemographic characteristics of participants in he original FDA survey. Table 4 








Respondent Sociodemographics (N = 235) 
Sociodemographic % n 
Age 
18-24 38.3 90 
25-34 25.1 59 
35-44 11.5 27 
45-54 6.8 16 
55-64 4.3 10 
65+ 1.3 3 
Gender 
Male 38 89 
Female 62 144 
Ethnicity (multiple responses permitted) 
American Indian/Alaska Native 3 7 
Asian/Pacific Islander 1.3 3 
Black/African American 9.5 22 
Hispanic/Latino 6 14 
White (Caucasian) 80.5 186 






Sociodemographic % n 
Income 
$0–$24,999 24.9 51 
$25,000–$49,999 18 37 
$50,000–$99,999 24.9 51 
$100,000–$149,999 12.2 25 
$150,000+ 20 41 
Education 
Completed high school or less 7.4 15 
Some college 46 94 
Completed college or more 46.6 95 
Marital status 
Married 28 66 
Single 60 140 
Widowed 1.3 3 
Divorced 9.4 22 
Separated 0.9 2 
Health status 
Excellent/very good 58 136 






Explanation of Tables 
SPSS Version 21 was the statistical program used to perf rm ANOVAs. ANOVA 
determines if there is a significant difference between the means of at least two 
independent variables or groups. The results were grouped by the applicable hypothesis. 
Results are presented in the following ANOVA tables with abbreviated question titles. 
The corresponding full-text survey questions are presented in Table 2.  
Hypothesis 1 
 Hypothesis 1 related to physician office visits and exposure to DTCA: 
H10: There is no relationship between patient exposure to DTCA and subsequent 
physician office visits. 
H1A: There is a direct association between patient exposure to DTCA and 
subsequent physician office visits. 
Patient exposure to DTCA was associated with several aspects of physician office 
visits. As shown in Table 5, seeing an advertisement for prescription drugs was 
associated with rating the interaction with a doctor as positive [F = (1, 229) = 15.94, p = 
0.00]. There were no statistically significant differences (p < 0 .025) between seeing an 
advertisement for prescription drugs and more recent visits to a doctor, a nonroutine visit, 
and talking to doctor about a prescription drug.   
 The number of different prescription drug advertisments that were seen over the 
past year was associated with rating the interaction with a doctor as positive [F = (11, 





differences (p < 0.025) between the number of different prescription drug advertisements 
that were seen over the past year and talking to a doctor about a prescription drug, the 
timing of the last office visit, or the type of visit (routine or nonroutine). 
 Analytical results in Table 7 demonstrate that viewing a prescription drug 
advertisement that caused a search for more information was associated with a more 
recent visit to a doctor, nurse practitioner, or physician’s assistant [F = (1,228) = 8.05, p 
= 0.01], and talking to a doctor about a prescription drug [F = (1,231) = 34.70, p = 0.00]. 
There were no statistically significant differences (p < 0 .025) between viewing a 
prescription drug advertisement that caused a search fo  more information and a 
nonroutine visit or rating the interaction with a doctor. 
 As shown in Table 8, there were no statistically significant differences (p < 0 
.025) between looking for additional information (side effects, interactions with other 
drugs/medicines, dangers, and/or costs) and the timing of the last visit, type of visit, 








One-Way ANOVA for Physician Office Visits: Question 3, Recall DTCAs 
Visit/purpose Factor 
Sum of  
squares df 
Mean 
square F Sig. 

















































Note. Significance was assessed at the *p < 0.025 level. Last visit, routine visit, talk 
about Rx, and rate interaction correspond to survey questions 1, 2, 9 and 14 respectively, 
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Note. Last visit, routine visit, talk about Rx, and rate interaction correspond to survey 
questions 1, 2, 9 and 14 respectively, as all survey qu stions are displayed in Table 2. 
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Note. Last visit, routine visit, talk about Rx, and rate interaction correspond to survey 
questions 1, 2, 9 and 14 respectively, as all survey qu stions are displayed in Table 2. 
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Note. Last visit, routine visit, talk about Rx, and rate interaction correspond to survey 
questions 1, 2, 9 and 14 respectively, as all survey qu stions are displayed in Table 2. 







 Viewing a prescription drug advertisement that caused a search for more 
information was associated with a more recent visitto a doctor, nurse practitioner, or 
physician’s assistant [F = (1,228) = 8.05, p = 0.01], and talking to a doctor about a 
prescription drug [F = (1,231) = 34.70, p = 0.00], as shown in Table 9. There were no 
statistically significant differences (p < 0 .025) between viewing a prescription drug 
advertisement that caused a search for more information nd a nonroutine visit, the type 
of visit or how the interaction with the doctor was r ted. 
 As shown in Table 10, agreeing that advertisements for prescription drugs help 
make better decisions about health was associated wi h talking to a doctor about a 
prescription drug [F = (4,230) = 2.94, p = 0.02]. However, there were no statistically 
significant differences (p < 0 .025) between agreeing that advertisements for prescription 
drugs help make better decisions about health and the timing of the last office visit, the 
type of visit, or the rating for interaction with a doctor.   
 Several sociodemographic variables were associated wi h more physician office 
visits. Better self-reported health status was associated with rating the interaction with a 
doctor as positive [F = (4,226) = 4.20, p = 0.00], as shown in Table 11. There were no 
statistically significant differences (p < 0 .025) between the self-reported health status 
and not talking to a doctor about a prescription drug, timing of the last visit or the type of 
visit. 
 In Table 12, being a male participant was associated with a more recent visit [F = 





7.69, p = 0.01]. There were no statistically significant differences (p < 0 .025) between 
being male participant and the type of visit or rating the interaction with the doctor.   
 As shown in Table 13, being married was associated with talking to a doctor 
about a prescription drug [F = (4,228) = 3.23, p = 0.01]. There were no statistically 
significant differences (p < 0 .025) between marital status and the timing of the last visit, 
the type of visit, or rating the interaction with the doctor.   
 As shown in Table 14, a lower education level was associated with talking to a 
doctor about a prescription drug [F = (6, 227) = 3.34, p = 0.00]. There were no 
statistically significant differences (p < 0 .025) between education and the timing of the 
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Note. Last visit, routine visit, talk about Rx, and rate interaction correspond to survey 
questions 1, 2, 9 and 14 respectively, as all survey qu stions are displayed in Table 2. 
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Note. Last visit, routine visit, talk about Rx, and rate interaction correspond to survey 
questions 1, 2, 9 and 14 respectively, as all survey qu stions are displayed in Table 2. 
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Note. Last visit, routine visit, talk about Rx, and rate interaction correspond to survey 
questions 1, 2, 9 and 14 respectively, as all survey qu stions are displayed in Table 2. 
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Note. Last visit, routine visit, talk about Rx, and rate interaction correspond to survey 
questions 1, 2, 9 and 14 respectively, as all survey qu stions are displayed in Table 2. 
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Note. Last visit, routine visit, talk about Rx, and rate interaction correspond to survey 
questions 1, 2, 9 and 14 respectively, as all survey qu stions are displayed in Table 2. 
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Note. Last visit, routine visit, talk about Rx, and rate interaction correspond to survey 
questions 1, 2, 9 and 14 respectively, as all survey qu stions are displayed in Table 2. 








 Hypothesis 2 related to requests for a specific prescription medication and 
exposure to DTCA: 
H20: There is no relationship between patient exposure to DTCA and a patient 
asking subsequently for a corresponding prescription drug. 
H2A: There is a direct association between patient exposure to DTCA and a 
patient asking subsequently for a corresponding prescription drug. 
Patient exposure to DTCA was associated with patients asking for a prescription 
drug. As shown in Table 15, there were no statistically significant differences (p < 0 .025) 
for seeing or hearing advertisements and asking whether there might be a prescription 
drug to treat the patient/survey participant, the expectation for a prescription, the 
mentioning of an advertisement, or to the doctor’s utcome.   
 The number of different prescription drug advertisments that were seen was 
associated with expecting a doctor to prescribe a drug [F = (11,219) = 3.31, p = 0.00] and 
a doctor giving a prescription, recommending a prescription, recommending an over-the-
counter drug, or recommending a behavior or lifestyl  change [F = (11,222) = 2.23, p = 
0.01], as shown in Table 16. However, there were no statistically significant differences 
(p < 0 .025) between the number of different prescription drug advertisements and asking 
whether there might be a prescription drug to treat the patient/survey participant or 





 As shown in Table 17, seeing an advertisement for a prescription drug in print or 
on television that caused a patient/survey participant to look for more information was 
associated with expecting a doctor to prescribe a drug [F = (1,228) = 16.25, p = 0.00], 
asking whether there might be a prescription drug to treat the patient/study participant [F 
= (1,226) = 43.23, p = 0.00], mentioning a prescription drug advertisement that was seen 
or heard [F = (1,229) = 43.33, p = 0.00], and a doctor giving a prescription, 
recommending a prescription, recommending an over-the-counter drug, or recommending 
a behavior or lifestyle change [F = (1,231) = 37.51, p = 0.00]. 
 As shown in Table 18, looking for side effects, interactions, dangers, or cost 
information about a prescription drug was associated with mentioning a prescription drug 
advertisement that was seen or heard [F = (2,230) = 7.76, p = 0.00] and a doctor giving a 
prescription, recommending a prescription, recommending an over-the-counter drug, or 
recommending a behavior or lifestyle change [F = (2,232) = 14.90, p = 0.00]. There were 
no statistically significant differences (p < 0 .025) between looking for side effects, 
interactions, dangers, or cost information about a prescription drug and expecting a 
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Note. Expect Rx, Might Rx, Meaningful, and Did Dr. give Rx correspond to survey 
questions 10, 11, 12, and 13, respectively, as all survey questions are displayed in Table 
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Note. Expect Rx, Might Rx, Meaningful, and Did Dr. give Rx correspond to survey 
questions 10, 11, 12, and 13, respectively, as all survey questions are displayed in Table 
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Note. Expect Rx, Might Rx, Meaningful, and Did Dr. give Rx correspond to survey 
questions 10, 11, 12, and 13, respectively, as all survey questions are displayed in Table 
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Note. Expect Rx, Might Rx, Meaningful, and Did Dr. give Rx correspond to survey 
questions 10, 11, 12, and 13, respectively, as all survey questions are displayed in Table 








 ANOVA results shown in Table 19 indicate that a prescription drug advertisement 
that caused a patient to ask a doctor about a new medical condition or illness was 
associated asking whether there might be a prescription drug to treat the patient/study 
participant [F = (1,224 ) = 31.98, p = 0.00], mentioning a prescription drug advertisement 
that was seen or heard [F = (1,227) = 64.90, p = 0.00], and a doctor giving a prescription, 
recommending a prescription, recommending an over-the-counter drug, or recommending 
a behavior or lifestyle change [F = (1,229) = 23.60, p = 0.00]. However, there were no 
statistically significant differences (p < 0 .025) for expecting a doctor to prescribe a drug.   
 Liking to see prescription drug advertisements wasassociated with asking 
whether there might be a prescription drug to treat the patient/study participant [F = 
(4,223) = 4.53, p = 0.00] and mentioning a prescription drug advertis ment that was seen 
or heard [F = (4,226) = 9.19, p = 0.00], as shown in Table 20. However, there were no 
statistically significant differences (p < 0 .025) between liking to see prescription drug 
advertisements and expecting a doctor to prescribe a drug or for the doctor giving a 
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Note. Expect Rx, Might Rx, Meaningful, and Did Dr. give Rx correspond to survey 
questions 10, 11, 12, and 13, respectively, as all survey questions are displayed in Table 
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Note. Expect Rx, Might Rx, Meaningful, and Did Dr. give Rx correspond to survey 
questions 10, 11, 12, and 13, respectively, as all survey questions are displayed in Table 







 Agreeing that advertisements for prescription drugs help make better decisions 
about health was associated with asking whether there might be a prescription drug to 
treat the patient/study participant [F = (4,225) = 4.08, p = 0.00] and mentioning a 
prescription drug advertisement that was seen or heard [F = (4,228) = 6.68, p = 0.00], as 
shown in Table 21. However, no statistically significant differences (p < 0 .025) were 
found between agreeing that advertisements for prescription drugs help make better 
decisions about health and expecting a doctor to prescribe a drug or for the doctor giving 
a prescription, or recommending a behavior or lifestyl  change.   
 Several sociodemographic variables were associated wi h patients asking for 
prescription drugs. As shown in Table 22, better self-reported health status was 
associated with not mentioning a prescription drug advertisement that was seen or heard 
[F = (4,228) = 4.19, p = 0.00] and a doctor not giving a prescription, recommending a 
prescription, recommending an over-the-counter drug, or recommending a behavior or 
lifestyle change [F = (4,230) = 3.27, p = 0.01]. But self-reported health status was not 
associated with expecting a prescription or asking if there might be a prescription drug to 
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Note. Expect Rx, Might Rx, Meaningful, and Did Dr. give Rx correspond to survey 
questions 10, 11, 12, and 13, respectively, as all survey questions are displayed in Table 
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Note. Expect Rx, Might Rx, Meaningful, and Did Dr. give Rx correspond to survey 
questions 10, 11, 12, and 13, respectively, as all survey questions are displayed in Table 







 As shown in Table 23, the number of hours per week spent using the Internet or 
World Wide Web was associated with mentioning a prescription drug advertisement that 
was seen or heard [F = (36, 191) = 1.6, p = 0.02]. Even so, no statistically significant 
differences (p < 0 .025) were found between the number of hours per we k using the 
Internet or World Wide Web and the expectation for a prescription, asking whether there 
might be a prescription drug to treat the patient/study participant, or for a doctor giving or 
recommending a prescription. 
 Being a male patient/study participant was associated with going to a visit and not 
expecting a doctor to prescribe a drug [F = (1,228) = 5.65, p = 0.02], as shown in Table 
24. No statistically significant differences (p < 0 .025) were found for being male 
patient/study participant and the expectation for a p escription, mentioning of an 
advertisement, or to the doctor’s prescribing outcome.   
 Being married was associated with not mentioning a prescription drug 
advertisement that was seen or heard [F = (4,226) = 4.11, p = 0.00], as shown in Table 
25. Still, no statistically significant differences (p < 0 .025) were indicated between 
marital status and a doctor giving a prescription, recommending a prescription, 
recommending an over-the-counter drug, or recommending a behavior or lifestyle 
change, the expectation for a prescription, or asking whether there might be a prescription 
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Note. Expect Rx, Might Rx, Meaningful, and Did Dr. give Rx correspond to survey 
questions 10, 11, 12, and 13, respectively, as all survey questions are displayed in Table 
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Note. Expect Rx, Might Rx, Meaningful, and Did Dr. give Rx correspond to survey 
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Note. Expect Rx, Might Rx, Meaningful, and Did Dr. give Rx correspond to survey 
questions 10, 11, 12, and 13, respectively, as all survey questions are displayed in Table 







 As shown in Table 26, no statistically significant differences (p < 0 .025) were 
indicated between higher levels of education and asking whether there might be a 
prescription drug to treat the patient/study participant, mentioning a prescription drug 
advertisement that was seen or heard, or the expectation for a prescription or to the 
doctor’s prescribing outcome. Likewise, as shown in Table 27, there were no statistically 
significant differences (p < 0 .025) between race and the expectation for a prescription, 
asking if there was a prescription drug for treatment, mentioning an advertisement that 
was seen or heard, or the doctor’s response. 
Summary 
 The purpose of this study was to determine if an association exists between 
DTCA and health care seeking behaviors and to explore patient perspectives on the issue 
as they relate to the overall health care experience. This study was quantitative and the 
data were analyzed using descriptive statistics and ANOVA, which were employed to test 
the hypotheses of this study. A two-step technique was used, as applicable, using SPSS, 
Version 21. First, the independent variables and the dependent variable were loaded into 
an ANOVA to determine the predictive power of the equation. Next, the applicable 
sociodemographic variable(s) were loaded into an equation with the dependent variable 
to assess their impact. Finally, the predictive power of the two equations was compared to 
determine the predictive value of DTCA. All data analyses and statistical significance 
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Note. Expect Rx, Might Rx, Meaningful, and Did Dr. do Rx correspond to survey 
questions 10, 11, 12, and 13, respectively, as all survey questions are displayed in Table 
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Note. Expect Rx, Might Rx, Meaningful, and Did Dr. do Rx correspond to survey 
questions 10, 11, 12, and 13, respectively, as all survey questions are displayed in Table 






 For Hypothesis 1, there was limited evidence that college-affiliated adult 
patients/study participants who saw advertisements for prescription drugs were more 
likely to (a) rate their doctor interactions higher; (b) talk to their doctor about a 
prescription drug; and (c) have a recent visit to their doctor, nurse practitioner, or 
physician’s assistant. Lower health status, being a man, being married, and lower 
education levels were all associated with more office visits.  
 For Hypothesis 2, there was limited evidence that college-affiliated adult 
patients/study participants who saw advertisements for prescription drugs or searched for 
additional information about a prescription drug were more likely to (a) ask their doctor if 
there was a prescription drug to treat them; (b) expect a doctor to prescribe a drug; (c) 
have a doctor give them a prescription, recommend a prescription, recommend an over-
the-counter drug, or recommend a behavior or lifestyl  change; and (d) mention a 
prescription drug to their doctor. Lower health status, the number of hours spent on the 
Internet or World Wide Web per week, being a woman, being single, higher education 
levels, and being an ethnic minority were all associated with requesting prescription 
drugs. Chapter 5 includes an interpretation of the findings, discussion of the findings, the 
limitations of the study, implications for social change, recommendations for future 






Chapter 5: Discussion, Conclusions, and Recommendations 
Summary 
 The purpose of this quantitative study was to determine if an association exists 
between DTCA and health care-seeking behaviors. The theoretical framework consisted 
of social learning theory, information integration theory, and prospect theory. The 
research questions addressed in this study included identifying if exposure to DTCA (a) 
is associated with physician office visits, (b) influences a patient/physician conversation 
regarding a prescription, (c) influences requesting a prescription, and (d) has an impact 
on patients’ ratings of the overall interaction with the physician. Data were derived from 
an online survey adapted from an FDA study (HHS, 2004). Participants included 235 
college-affiliated adults. Data were analyzed using descriptive statistics and ANOVAs. 
The Bonferroni correction was used to control the family-wise Type I error rate. 
According to study results, seeing advertisements for prescription drugs was associated 
with a recent doctor visit, asking whether a prescription drug was available to treat a 
condition, expecting to receive a prescription, receiving a prescription, and mentioning a 
prescription drug to a doctor. Future researchers should consider a non-college-affiliated 
sample and the post-implementation impact of the Affordable Care Act. Social change 
implications of the study include better consumer education and protection, more 
responsible health care policy and corporate decision making, and the potential 






Significance of the Study 
The United States is ranked low on quality, efficien y, access, equity, and ability 
for citizens to lead longer and healthier lives (McCarthy, 2014; Mathaisel & Comm, 
2014). Pharmaceutical companies are viewed as one of several contributors to the 
sustainability of the health care industry. Therefo, this study can provide information to 
focus DTCA efforts to help improve availability, dependability, capability, affordability, 
and marketability for prescription drugs. The increas  in the use of DTCA by 
pharmaceutical companies suggests that this practice is profitable. Given the potential 
opportunity for positive or negative results, more assessments of DTCA are needed to 
understand its impact. This study could help to address this gap in the literature and offer 
opportunities for focusing further research in more appropriate areas.  
This study could also provide greater insight into opportunities to mitigate the 
potential impacts of DTCA. Overuse and inordinate cost burdens on patients are all 
potential negative outcomes resulting from inappropriate DTCA. Additionally, physicians 
feeling pressured to switch to new, more profitable medications may be another negative 
outcome that this study can help to better understand. Understanding the impact of DTCA 
will provide managers and executives, as well as governments and legislatures, with 
information that can help to guide policy development, strategies, and health plan 
decisions. Additional guidance can help to ensure that patients have adequate information 






Several assumptions were made in this study. Among them are the following. It 
was assumed that all participants responded truthfully to the survey and all participants 
had access to the Internet or a computer. Additionally, I assumed that respondents to the 
HHS (2004) survey, which was used for comparative purposes, answered the questions 
honestly. It was also assumed that the established tatistical methods employed in this 
study were reliable and representative of the natiol population. Additionally, I assumed 
that the influence of mass media on society (Bandura, 2001) is substantial and the 
pharmaceutical industry is aggressive in nature (Angell, 2011). 
Limitations 
Several limitations must be acknowledged relative to this study. Generalizability 
is limited because this study was open to only college-affiliated adults. Additionally, due 
to the reliance upon the online university participant pool and SurveyMonkey, 
participants had to have online access. In this sample of 235 participants, there was an 
underrepresentation of many racial ethnic groups, with 80.5% of participants self-
reporting as members of the White/Caucasian American category. Given the statistically 
significant differences identified across sociodemographic characteristics, this disparity 
could have affected the outcomes. Additionally, there may be differences relative to 
ethnic minorities who were not discovered, given the small representation of this 
population in this study. Overall, due to the nature of the survey—personal health—





students are traditionally younger, more educated, an  in other ways different from 
members of society in general. 
Interpretation of Findings 
The association between DTCA and health care-seeking behaviors and patient 
perspectives on the issue relative to the patient’s overall health care experience were 
studied. SPSS was used to analyze data. All data anlyses and statistical significance 
were assessed at the p < 0.025 level. The following research questions were addressed in 
detail and were the catalyst for this study:  
1. What is the relationship between direct-to-consumer advertising (DTCA) 
and physician office visits? 
2. What is the relationship between direct-to-consumer advertising (DTCA) 
and patients asking for a prescription?  
These questions were researched through two hypotheses. Hypothesis 1 related to 
physician office visits and exposure to DTCA: 
H10: There is no relationship between patient exposure to DTCA and subsequent 
physician office visits. 
H1a: There is a direct association between patient exposure to DTCA and 
subsequent physician office visits. 






H20: There is no relationship between patient exposure to DTCA and a patient 
asking subsequently for a corresponding prescription drug. 
H2a: There is a direct association between patient exposure to DTCA and a 
patient asking subsequently for a corresponding prescription drug. 
 For Hypothesis 1, there was limited evidence that college-affiliated adult study 
participants who saw advertisements for prescription drugs were more likely to (a) rate 
their doctor interactions higher; (b) talk to their doctor about a prescription drug; and (c) 
have a recent visit to their doctor, nurse practitioner, or physician’s assistant. Lower 
health status, being a man, being married, and lower education levels were all associated 
with more office visits.  
 For Hypothesis 2, there was limited evidence that college-affiliated adult study 
participants who saw advertisements for prescription drugs or searched for additional 
information about a prescription drug were more likly to (a) ask their doctor if there was 
a prescription drug to treat them; (b) expect a doctor to prescribe a drug; (c) have a doctor 
give them a prescription, recommend a prescription, recommend an over-the-counter 
drug, or recommend a behavior or lifestyle change; and (d) mention a prescription drug to 
their doctor. Lower health status, the number of hours spent on the Internet or World 
Wide Web per week, being a woman, being single, higher education levels, and being an 





Implications for Social Change 
The United States and New Zealand are the only two industrialized nations that 
permit DTCA, and pharmaceutical firms in these countries have the highest profit 
margins of any industries in these two countries (Hawthorne, 2010). With increasingly 
greater numbers—more than 50%—of all people in the United States taking prescription 
drugs, the total annual retail sales of prescription drugs exceeding $300 billion a year, and 
more than $28 million being spent by PhRMA to lobby members of Congress, it is 
difficult for the FDA to ensure consumer protection (PhRMA, 2011). The significant 
societal dependency on prescription drugs provides a potentially endless supply of 
individuals who are vulnerable to abuse. Deadly side effects and contraindications are but 
a few of the many dangers associated with prescription drugs. Additionally, the principal-
agent relationship between consumers and physicians provides an example of the 
potential patient vulnerabilities.    
The most significant findings of this study are that DTCA is associated with 
patients asking more questions, having more office v sits and patients having a lower 
overall health status. As DTCA is associated with patients asking their physicians more 
questions, this increased communication could help patients make better decisions about 
the potential risks, benefits and costs of prescription drugs. As patients, especially those 
who perceive themselves as less healthy, attempt to understand the very complex issues 





Given that DTCA is associated with more office visit, physicians can help 
patients to better understand this tendency as well as the positive or negative impacts. 
Physicians are trained to help patients make informed decisions about their health care. 
Being aware of the DTCA and office visits association can help physicians assist patients 
in taking better care of themselves, minimizing unnecessary office visits, and reducing 
their out of pocket costs. 
Evidence from this study also suggests a strong association between DTCA and 
patients with a lower health status. Knowledge of this association can help patients and 
physicians to focus their efforts on ensuring a positive social impact. Awareness of this 
relationship can change patient, physician and healt care policy maker decision making 
and reduce the likelihood of adverse clinical and fi ancial implications. This could 
provide a significant opportunity to help the least healthy of society to greatly improve 
their health, quality of life and ability to return to work if they have been hindered by 
their poor health status. 
Additionally, health care policy has a financial impact and drives corporate and 
individual decisions and behavior. This study provides a clearer understanding of what 
aspects of DTCA should be carefully considered in the development of local and national 
health care policy. This understanding will reduce th  probability of unintended negative 
consequences from legislation and policy.  
Other social change implications of this study include consumer protection in a 





seeking-behavior. The discovered link between the adv rtising component of marketing 
campaigns and health care-seeking behavior can potetially drive an overuse of 
unnecessary medications and a subsequent unnecessary reduction in health status and 
added cost burden for patients. FDA guidance and regulations, federal and state health 
care policy, and patient interaction with health care professionals are all documented 
factors that may be touched by DTCA. As a result, it is important to understand the 
impact of DTCA because it can be used to improve the health status and economic 
prosperity of society. This knowledge can also be us d to better manage the potential for 
abuse, given the industry financial incentives. Using the identified significant aspects of 
DTCA, physicians have a better understanding of the aspects of DTCA that impact 
patient decision making. Having this information could help physicians to develop more 
effective ways of communicating with patients and developing more effective care plans. 
Recommendations for Further Study 
 Future researchers can address the limitations of this study by investigating a 
larger sample size that is not limited by Internet access, college affiliation, or age. 
Although the type of medium used in this study was not restrictive geographically, 
cultural and geographic preferences and differences may still have existed. 
This study focused on participants associated with an academic community. A 
study that collects information regarding students’ major and current occupation might 
also provide additional insights regarding attitudes and behaviors relative to DTCA. 





experience, and training. As an example, undergraduate nursing students may provide 
different answers than undergraduate business students. The degree to which patients 
truly comprehend and understand the information in DTCA could provide an additional 
research opportunity. Finally, an assessment of how much information patients retain 
from DTCA and whether that retention is tempered or enhanced by health status or the 
length of the patient-physician relationship. Furthe  research may reveal that different 
degrees of retention exist for patients with severe conditions such as terminal cancer, and 
patients with other conditions such as a minor cold. Additional research may also reveal 
that the length of an established physician-patient r lationship may mitigate the impact of 
DTCA. 
Quantifying the financial impact of DTCA could provide insight into corporate 
incentives. Research that better clarifies the incentiv s and disincentives for 
pharmaceutical companies could help to drive safer corporate decisions and potentially 
influence health care policy. Research in this area could help to ensure that corporate 
incentives are aligned with desired positive patient outcomes. 
 The FDA study (HHS, 2004) was one of the initial studies to focus on the doctor-
patient relationship and its broad implications for health care. The OPDP continues 
research projects on this topic, with current studies including an examination of online 
DTC drug promotion, experimental study of format variations in the brief summary of 





promotion. With students as participants, this study provided information that could 
enhance the overall patient care experience. 
 Finally, given the full implementation of the unprecedented employer, health care 
industry, and individual changes required under the Affordable Care Act, future research 
may produce different results. Signed into law by President Barack Obama in 2010, the 
Affordable Care Act seeks to improve access to the U.S. health care system and increases 
individual responsibility as it relates to a person’ health care. Once fully implemented in 
the coming years, employer requirements to provide coverage for older children, 
individual mandates to obtain coverage or be subjected to a penalty, and health care 
industry performance requirements for payment could likely produce different research 
findings and opportunities. Future research could also help with the assessment of the 
impact of the Affordable Care Act. 
Concluding Remarks 
A few of the hypothesized associations were not supported quantitatively, so this 
study can contribute to the development of new knowledge by specifying the aspects of 
DTCA that are associated with patient behaviors and perceptions. The findings of this 
study outline the specific models that more clearly explain the impact of DTCA. Social 
change implications of the study include consumer protection in a risky market and the 
prevention of unnecessary, expensive, and potentially d ngerous drug- and health care-
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Appendix A: Direct-to-Consumer (DTC) Promotion of Prescription Drugs Survey 
 1. How long has it been since the last time you saw a doctor, a nurse practitioner, or a 
physician’s assistant where you talked about a healt  condition or concern of your own, 
not for a child or parent or someone else?  
Within the last week 
1 to 4 weeks ago 
5 weeks to 3 months ago 
4 to 6 months ago 
7 to 11 months ago 
1 year ago 
More than 1 year ago 
Never 
 










4. Have you seen or heard any ads for prescription drugs in any of the following ways: 
(check all that apply) 
a. On television 
b. On the radio 
c. In a magazine 
d. In a newspaper 
e. On the Internet 
f. In a letter, flyer or announcement you got in the mail 





h. In a grocery store or pharmacy 
i. Anywhere else? (please specify)    
 
5. In the last year, how many different prescription drugs do you recall seeing advertised 












More than ten 
 
6. Thinking about the ads you have seen both in print and on television, has an 
advertisement for a prescription drug ever caused you to look for more information, for 




7. What information did you look for?  
Side effects 
Interactions with other drugs/medicines 
Dangers of the drug 
Cost of the drug 
Other (please specify)   
 





















12. Did you mention an advertisement you saw or head for a drug or bring information 
about the advertised drug with you? 
Yes, I mentioned an ad I saw or heard 




13. Did your doctor do one or more of the following: [Select all that apply] 
Give you the prescription drug you asked about 
Not give you the prescription drug you asked about 
Recommend a different prescription drug 
Recommend an over-the-counter drug 
Recommend no drug 
Recommend that you make changes in your behavior or lifestyle 













15. I like seeing advertisements for prescription drugs. 
Agree Strongly 
Agree Somewhat 



















18. How many hours in a typical week do you use the internet or world wide web at 
home and at work? 






Number of hours?    
 











21. What is the last grade of school that you completed?  
Grade school or less 
Some high school 
Completed high school 
Some college 
Completed college 
Graduate school or more 
Other beyond high school (business, technical, etc.)
 
22. Are you of Hispanic, Latino, or Spanish origin? 
No, not of Hispanic, Latino, or Spanish origin 
Yes, Mexican, Mexican American, Chicano 
Yes, Puerto Rican 
Yes, Cuban 
Yes, another Hispanic, Latino, or Spanish origin 
Please state origin, for example Argentinean, Colombian, Dominican, Nicaraguan, 
Salvadoran, or Other.     
 






Black, African American, or Negro 








Guamanian or Chamorro 
Samoan 
Other Asian, Other Pacific Islander, or Other Race – (For example Laotian, Thai, 
Pakistani, Cambodian, Fijian, Tongan, or other)  
 
 





Survey adapted Patient and Physician Attitudes and Behaviors Associated with DTC 
Promotion of Prescription Drugs, from U.S. Department of Health And Human Services, 





Appendix B: Direct-to-Consumer Advertising and Patien  
Healthcare Behaviors Consent Form (Participant Pool) 
 You are invited to participate in a study of direct-to-consumer drug advertising 
(DTCA) and health care behaviors that you may have experienced in the last 12 months 
of your adult life. You are selected as a potential participant in this study because you are 
an adult and you are available through the Walden Participating Pool website voluntarily. 
I ask that you read this form and ask any question you may have before agreeing to be in 
the study. This study is being conducted by Patrici Kennedy-Tucker, a doctoral 
candidate at Walden University. 
 Background information: The purpose of this study is to gain an understanding 
of DTCA and health care behaviors and to explore patient perspectives on the issue as 
they relate to the overall health care experience.   
 Procedures: If you agree to participate in this study, please read this informed 
consent form and go ahead to respond to the survey qu stions. I will ask you to complete 
the demographic questions at the end of the survey.  There are a total of 23 questions and 
you should be able to complete the survey in 5-8 minutes.  
 Confidentiality: The survey is anonymous.  The records of this study will be kept 
private.  The research records will be kept in encrypted form. 
 Voluntary nature of the study: Your participation in the study is voluntary and 
you are free to withdraw at any time during the process of completing the survey. Your 





employer in any way. If you decide to withdraw your participation you may do so 
without affecting your relationship with your current schooling or employment. 
 Risks and benefits of being in the study: There are no physical risks and no 
benefits due to participating in the study. However, the proposed study may provide 
social change implications to include consumer protection in a risky market and 
prevention of unnecessary and expensive drug and health care seeking behavior.  
Participants are not obligated to complete any part of the survey with which they are not 
comfortable. 
 Contacts and questions: The researcher conducting this study is Patricia 
Kennedy-Tucker. The university IRB may be contacted by e-mail at IRB@waldenu.edu 
if you have any question about your right as participants. 
 Statement of consent: I have read the above information. I have asked any 
necessary questions and received answers. I consent to participate in the study. 
In order to protect your privacy, signature is not being collected and your completion of 
survey would indicate your consent if you choose to participate. You may keep or print a 






Appendix C: Direct-to-Consumer (DTC) Advertising of Prescription Drugs  
Informed Consent 
 You are invited to participate in a study of direct-to-consumer drug advertising 
(DTCA) and health care behaviors that you may have experienced in the last 12 months 
of your adult life. You are selected as a potential participant in this study because you are 
an adult and your student status. I ask that you read this form and ask any question you 
may have before agreeing to be in the study. This study is being conducted by Patricia 
Kennedy-Tucker, a doctoral candidate at Walden Univers ty.  
 Background information: The purpose of this study is to gain an understanding 
of DTCA and health care behaviors and to explore patient perspectives on the issue as 
related to the overall health care experience.  
 Procedures: If you agree to participate in this study, please read this informed 
consent form and go ahead to respond to the survey qu stions. There are a total of 24 
questions and you should be able to complete the survey in 5-8 minutes.  
 Confidentiality: The survey is anonymous. The records of this study will be kept 
private. The research records will be kept in encrypted form.  
 Voluntary nature of the study: Your participation in the study is voluntary and 
you are free to withdraw at any time during the process of completing the survey. Your 
decision to participate in this study will not affect your relationship with your school or 





 Risks and benefits of being in the study: There are no physical risks and no 
benefits due to participating in the study. However, the proposed study may provide 
social change implications to include consumer protection in a risky market and 
prevention of unnecessary and expensive drug- and health care-seeking behavior. 
Participants are not obligated to complete any part of the survey with which they are not 
comfortable.  
 Payment: No payment, thank you gifts, or reimbursements are provided by the 
researcher to participants.  
 Contacts and questions: The researcher conducting this study is Patricia 
Kennedy-Tucker. The university IRB may be contacted by e-mail at IRB@waldenu.edu 
if you have any question about your right as participants. Walden University’s approval 
number for this study is 05-21-13-0019798 and it expires on May 20, 2014.  
 Results: If you would like to obtain a copy of the results of this study, please 
contact the researcher at the above e-mail.  
 Statement of consent: I have read the above information. I have asked any 
necessary questions and received answers. I consent to participate in the study. In order to 
protect your privacy, signature is not being collected and your completion of survey 
would indicate your consent if you choose to participate. You may keep or print a copy of 







Appendix D: Institutional Review Board (IRB) Approval Form 
Dear Ms. Kennedy-Tucker, 
 This e-mail is to notify you that the Institutional Review Board (IRB) has 
approved your application for the study entitled, Exploring the Effects of Direct-to-
Consumer Advertising of Drugs on Patients’ Health Care-Seeking Behavior 
 Your approval # is 05-21-13-0019798. You will need to reference this number in 
your doctoral study and in any future funding or publication submissions. Also attached 
to this e-mail is the IRB approved consent form. Please note, if this is already in an on-
line format, you will need to update that consent document to include the IRB approval 
number and expiration date. 
 Your IRB approval expires on May 20, 2014. One month before this expiration 
date, you will be sent a Continuing Review Form, which must be submitted if you wish to 
collect data beyond the approval expiration date. 
 Your IRB approval is contingent upon your adherence to the exact procedures 
described in the final version of the IRB application document that has been submitted as 
of this date. If you need to make any changes to your research staff or procedures, you 
must obtain IRB approval by submitting the IRB Requst for Change in Procedures 
Form. You will receive confirmation with a status update of the request within 1 week of 
submitting the change request form and are not permitt d to implement changes prior to 
receiving approval.  Please note that Walden Univers ty does not accept responsibility or 
liability for research activities conducted without the IRB's approval, and the University 
will not accept or grant credit for student work that fails to comply with the policies and 
procedures related to ethical standards in research. 
 When you submitted your IRB application, you made  commitment to 
communicate both discrete adverse events and general problems to the IRB within 1 
week of their occurrence/realization.  Failure to do so may result in invalidation of data, 
loss of academic credit, and/or loss of legal protections otherwise available to the 
researcher. 
 Both the Adverse Event Reporting form and Request for Change in Procedures 







 Researchers are expected to keep detailed records of their research activities (i.e., 
participant log sheets, completed consent forms, etc.) for the same period of time they 
retain the original data.  If, in the future, you require copies of the originally submitted 
IRB materials, you may request them from Institutional Review Board. 
 Please note that this letter indicates that the IRB has approved your research.  You 
may not begin the research phase of your dissertation, however, until you have received 
the Notification of Approval to Conduct Research e-mail.  Once you have received this 
notification by e-mail, you may begin your data collection.  
 Both students and faculty are invited to provide fe dback on this IRB experience 
at the link below: 
http://www.surveymonkey.com/s.aspx?sm=qHBJzkJMUx43pZegKlmdiQ_3d_3d 
Sincerely, 
Jenny Sherer, M.Ed., CIP 
Associate Director 




Office address for Walden University: 
100 Washington Avenue South 
Suite 900 
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